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Abstract 
The prognosis for lung cancer patients remains poor. Five year survival rates have 
been reported to be 15%. Studies have shown that dose escalation to the tumor can lead to 
better local control and subsequently better overall survival. However, dose to lung tumor 
is limited by normal tissue toxicity. The most prevalent thoracic toxicity is radiation 
pneumonitis. In order to determine a safe dose that can be delivered to the healthy lung, 
researchers have turned to mathematical models predicting the rate of radiation 
pneumonitis. However, these models rely on simple metrics based on the dose-volume 
histogram and are not yet accurate enough to be used for dose escalation trials. The 
purpose of this work was to improve the fit of predictive risk models for radiation 
pneumonitis and to show the dosimetric benefit of using the models to guide patient 
treatment planning. 
The study was divided into 3 specific aims. The first two specifics aims were 
focused on improving the fit of the predictive model. In Specific Aim 1 we incorporated 
information about the spatial location of the lung dose distribution into a predictive 
model. In Specific Aim 2 we incorporated ventilation-based functional information into a 
predictive pneumonitis model. In the third specific aim a proof of principle virtual 
simulation was performed where a model-determined limit was used to scale the 
prescription dose. 
The data showed that for our patient cohort, the fit of the model to the data was 
not improved by incorporating spatial information. Although we were not able to achieve 
a significant improvement in model fit using pre-treatment ventilation, we show some 
promising results indicating that ventilation imaging can provide useful information about 
vi 
 
lung function in lung cancer patients. The virtual simulation trial demonstrated that using 
a personalized lung dose limit derived from a predictive model will result in a different 
prescription than what was achieved with the clinically used plan; thus demonstrating the 
utility of a normal tissue toxicity model in personalizing the prescription dose.  
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Introduction 
Statement of Problem 
 The prognosis for lung cancer remains poor. Out of 1,529,560 new cancer cases in 
2010, 240,610 (15.7%) of those were lung cancers. The situation is further exacerbated by 
the poor prognosis for lung cancer patients. Lung cancer accounts for 29% of all cancer 
related deaths in men and 26% of all cancer related deaths in women. The 5 year survival 
rate for lung cancer has been reported to be 15% (1).  
 Several promising studies have shown that dose escalation to the tumor can lead 
to better local control and subsequently overall survival for non-small-cell lung cancer 
(NSCLC) patients (2-5). However, the dose to the tumor is limited by normal tissue 
radiation toxicity. For NSCLC patients, the most prevalent toxicity is radiation 
pneumonitis. Radiation pneumonitis occurs roughly in 10-20% of all radiation treatments 
of NSCLC (6) and usually manifests 1 to 6 months after the completion of radiation 
therapy. Symptoms of radiation pneumonitis can include cough, fever, shortness of 
breath, and if left untreated radiation pneumonitis can be lethal. 
 In order to determine a safe dose that can be delivered to the healthy lung tissue, 
clinicians and researchers have turned to mathematical models predicting the rate of 
radiation pneumonitis. The models describe a probability of developing radiation 
pneumonitis as a function of simple dose-volume metrics derived from the dose volume 
histogram (DVH). Researchers have also attempted to incorporate patient and clinical 
factors into predictive risk models (6, 7).  However, the data remains inconclusive and 
inconsistent. As a result, the models and therefore physicians rely mostly on population 
based dose-volume metrics to design and evaluate thoracic radiation treatment plans. 
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Better outcomes for lung cancer patients receiving radiation therapy strongly 
depend on treatment personalization. Treatment personalization can only be made 
possible by more reliable and accurate radiation pneumonitis dose response models. 
Therefore, the purpose of this study will be to improve the accuracy of predictive risk 
models for radiation pneumonitis and to show the dosimetric benefit of using the models 
to guide patient treatment planning.  
Current state of radiation therapy in lung cancer 
The survival rates for lung cancer remain poor. There are many reasons for the 
poor outcome for lung cancer patients. In many instances, physical symptoms may not be 
present at the time of initial diagnosis. In fact, up to 75% of patients that present with 
lung cancer have lesions that are unresectable due to the advanced stage of the disease or 
systematic spread (8). When surgery is not indicated, either because of the advanced stage 
of the tumor or because the patient is unable to tolerate surgery, a combination of 
radiation and chemotherapy is used. The exact treatment combination is dependent on the 
type and clinical staging of the disease. More than 80% of all lung cancers in the United 
States are NSCLC (1). For early stage NSCLC, surgery is often the treatment of choice 
with post-operative radiation therapy recommended if there is evidence of microscopic 
spread. Patients who are unable to tolerate surgery or who present with locally advanced 
NSCLC (defined as stage IIB-IIIB) are treated with a combination of radiation therapy 
and concurrent chemotherapy. Overall, approximately 75% of all lung cancer patients in 
our clinic receive radiation therapy. 
Although technological developments have enabled radiation therapy to deliver 
higher doses to the tumor, the biggest reason for death, for patients receiving radiation 
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therapy, remains local recurrence of the disease (9-11). Local recurrence can be defined 
as failure to eradicate the local disease. If the local disease is not controlled, it can 
subsequently lead to metastatic spread (12). Local control can be as low as 15% for 
patients who receive standard radiation doses of 66 Gy (13). Studies suggest that an 
improved local control rate can lead to a significant improvement in overall survival (2).   
Improved outcome shown with dose escalation 
Currently, the common clinical practice for thoracic radiation therapy is to deliver 
anywhere from 60-66 Gy to the target in either 1.8 or 2 Gy fractions. Several studies have 
proposed that one way to increase local control and subsequently overall survival is to 
escalate the dose to the tumor. As early as 1987, Perez et al (14) performed a study where 
they randomized patients to four different arms that delivered varying doses of radiation 
and found that higher doses of radiation were needed to improve tumor control.  In 
another study, Willner et al (15) retrospectively analyzed 135 NSCLC patients who were 
treated to radiation doses ranging from 30 to 80 Gy. They found that there was a clear 
dose effect on local control and overall survival. In more recent work, Kong et al. (4) 
analyzed a dose escalation trial in which NSCLC patients were treated to doses ranging 
from 63-103 Gy in 2.1 Gy fractions using three-dimensional conformal radiation therapy 
(3D-CRT). They found that the 5 year control rate was 12%, 35%, and 49%, for patients 
treated to doses of 63-69, 74-84, and 92-103 Gy, respectively. They concluded that higher 
doses of radiation were associated with improved outcomes. In another dose escalation 
trial, Bradley et al. (16) studied 177 patient with inoperable NSCLC. They found that 
local control rates of 50-78% were achieved with increasing radiation doses.  There are 
currently undergoing multi-institutional studies and protocols to evaluate the possibility 
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of escalating the dose to the tumor for lung cancer patients (17). Bradley et al (17) report 
in their initial findings that that the maximum tolerated dose was 74 Gy in 2 Gy fractions 
with three 3D-CRT and concurrent chemotherapy. The 74 Gy dose level was found to be 
well tolerated by patients and found to have low rates of radiation pneumonitis. 
Dose escalation limited by normal tissue toxicity 
Although increasing the radiation dose to the target has been shown to improve 
overall survival; it is impossible to increase the dose to the tumor without increasing the 
dose to the surrounding healthy tissue. Therefore, the doses that can be delivered to the 
target are limited by normal tissue toxicities. The two most common toxicities observed 
in thoracic radiation are acute esophagitis and radiation pneumonitis; with radiation 
pneumonitis being the more prevalent.  Radiation pneumonitis is an acute toxicity that 
develops within several weeks or months after radiation therapy. Symptoms of radiation 
pneumonitis include dry cough, low grade fever, shortness of breath, chest pain, and if 
left untreated radiation pneumonitis can be lethal (7). Treatment for radiation pneumonitis 
usually consists of steroids, oxygen, or assisted ventilation depending on the severity of 
the condition. 
In order to establish a common classification system, clinicians have tried to 
establish an objective endpoint that could be used to classify the severity of radiation 
pneumonitis. One suggestion has been to classify radiation pneumonitis based on 
dyspnea, which is defined as shortness of breath. The difficulty with dyspnea as an 
effective end-point is that the condition is non-specific and can be caused by various 
other medical conditions (such as infection and cardiac arrhythmia) not related to the 
radiation treatment (6). Most current radiation pneumonitis grading systems rely on 
5 
 
Table 1: CTCAE version 3.0 scoring criteria for 
radiation pneumonitis. 
medical intervention. One of the most common scoring systems called the Common 
Terminology Criteria for Adverse Events (CTCAE) (18) has been proposed by the 
National Cancer Institute. The scoring system (Table 1) consists of severity grades 1 
through 5, ranging from asymptomatic (grade 1) to death due to radiation pneumonitis 
(grade 5). The most common clinic endpoint used for analysis is grade 3, which is defined 
as severe symptoms, oxygen indicated, and limited self care in activities of daily living. It 
should be noted that there are different versions of the CTCAE criteria and several 
different groups have defined their own criteria for radiation toxicity. The different 
radiation pneumonitis scoring 
systems complicate the analysis of 
data from different groups and 
institutions. Tucker et al. (19) 
explored the impact of the scoring 
system on the relationship between 
radiation dose and pneumonitis. 
Their data demonstrated the 
importance of documenting the 
criteria for defining radiation 
pneumonitis. 
The range of symptomatic radiation pneumonitis has been reported to be 
anywhere from 5 to 50% (6). Some specific examples include a severe pneumonitis rate 
of 32% in a cohort of 223 patients treated at MD Anderson Cancer Center (20) and a 
pneumonitis rate of 14% from pooled data reported by Kwa et al. (21). However, it 
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should be noted that with newer data that includes newer treatment modalities such as 
IMRT, the pneumonitis rate has been reported to be lower. For example, Sura et al. (22)  
report a pneumonitis rate of 11% for patients treated with IMRT. Overall, with current 
radiation therapy methods, the risk of severe radiation pneumonitis is considered to be 
about 10-20%. 
Use of risk models to predict for radiation pneumonitis 
In order to try to predict a safe dose that can be given to the lung, researchers and 
clinicians have turned to predictive mathematical modeling. Mathematical models have 
been developed to calculate a normal tissue complication probability (NTCP) for 
radiation pneumonitis. One of the earliest models was developed by Lyman (20). The 
Lyman model is based on the assumption that the tolerance to radiation dose can be 
thought of as a normal distribution. Dose dependence can then be described as the 
integral of the normal distribution which produces a sigmoid curve. Mathematically, the 
Lyman model can be written as  
,  Equation 1 
where 
  Equation 2 
Deff is the effective dose, V is the volume, and m, n, and TD50 are model fitting 
parameters. The TD50 is the dose corresponding to 50% incidence of the radiation 
pneumonitis, m is related to the inverse of the slope of the sigmoid curve, and n is the 
volume parameter. A steeper slope (smaller m) indicates that there is more of a dose 
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response and that the binary data are separated well, while a smaller slope indicates a flat 
curve and a smaller dose response. The volume parameter (n) is a characteristic of the 
tissue and is closer to 1 when an organ is considered to be a “parallel” organ and closer to 
0 when the organ is considered to be a “serial” organ. The lung is considered to be a 
volume organ and therefore most studies suggest that the value of n is closer to 1 (6). The 
effective dose (Deff) is the dose-volume metric used as the input into the NTCP model. 
The physical meaning of the effective dose is dependent on the definition used to describe 
Deff. One common way to calculate the effective dose from the DVH was proposed by 
Mohan et al (23). The group proposed that the effective dose can be calculated with  
,  Equation 3 
where i loops over all the dose bins, v is the relative volume, and D is the dose. Equation 
3 is meant to reduce the heterogeneous dose distribution into a uniform dose given to a 
volume. With the n parameter set equal to 1 (as is the case in the lung) the effective dose 
gets reduced to the mean dose or in the case of lung, the mean lung dose (MLD). Using 
the DVH reduction scheme proposed by Mohan et al. (23) the expression in Equation 2 
can be re-written as  
.  Equation 4 
The expressions in Equations 1 and 4 are commonly called the Lyman-Kutcher-Burman 
(LKB) formulation of NTCP (24) which is the most widely used complication probability 
model in the literature (6). Throughout this work we will use the LKB formulation of 
NTCP described in Equations 1 and 4. 
It is important to note that there are other mathematical models that describe 
NTCP. One class of models uses other mathematical expressions to described a sigmoid 
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curve. Examples include the logistic and log-logistic models (25). A study by 
Seppenwoolde et al. (26) compared different sigmoid models and determined that the 
MLD formulation of the LKB model was the most accurate predictor of radiation 
pneumonitis. Another class of models is known as mechanistic models and tries to 
describe the biological phenomenon of radiation damage. One example of such a model is 
the “cluster” model proposed by Thames et al. (27). Other mechanistic models have been 
described that rely on the volume dependence (serial versus parallel) of a tissue (28). 
Finally, there are models that select several dosimetric features, instead of a single dose-
volume metric, to be included in prediction for radiation pneumonitis (28). 
The model parameters (for example m and TD50) are fit to a patient dataset using 
maximum likelihood analysis (29). Maximum likelihood analysis is a method of 
estimating parameters of a statistical model for binary observations. The likelihood metric 
can be described by 
,  Equation 5 
where i is the number of observations, y is the observation, and p is the probability of the 
observation. In terms of toxicity, i is the number of patients, y is the binary observation of 
whether or not the patient developed severe pneumonitis (yes or no), and p is equivalent 
to the NTCP. Substituting and re-arranging terms, the likelihood equation can be written 
as 
.  Equation 6 
For numerical reasons, the natural logarithm is taken of both sides of Equation 6 and the 
log-likelihood is computed. Finally, an optimization algorithm can be used to determine 
the model parameters (for example m and TD50) that maximize the log-likelihood. In 
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practice, often the negative of the log-likelihood is taken because algorithms may have 
routines for determining the minimum rather than the maximum. 
 In order to perform a complete statistical analysis, it is often desirable to obtain 
95% confidence limits on the fitting parameters. For a certain fitting parameter, the 95% 
confidence interval is determined by systematically varying the value of that particular 
fitting parameter, and optimizing the other parameters to calculate the maximum log-
likelihood. The lower and upper 95% confidence intervals are the value of the 
optimization parameter that equate to a log-likelihood reduction of 1.92. The value of 
1.92 is determined by taking half of the chi-squared distribution that equates to a 
significance level of 0.05. The shape of a log-likelihood curve as a function of one 
parameter is shown in Figure 1. It should be noted that the shape of the curve is not 
symmetric.  
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Factors affecting the risk of radiation pneumonitis 
As indicated in Equations 2-4, the two parameters most associated with the 
probability of developing radiation pneumonitis are dose and volume (6, 20, 30-33). 
Specifically, researchers have discussed metrics such as MLD and the volume receiving 
dose greater than a threshold (Vdose) value. For example, Wang et al (20) and Martel et al 
(31) found that patients with a higher MLD had a higher incidence of radiation 
pneumonitis. Wang et al (20) retrospectively analyzed 223 patients treated with definitive 
radiation therapy and concurrent chemotherapy. Using univariate analyses, they found 
that MLD was significantly associated with the risk of developing radiation pneumonitis. 
Martel et al (31) retrospectively analyzed the DVHs of 64 patients who had their normal 
lungs irradiated with 3D-CRT. They reported that patients who had radiation pneumonitis 
Figure 1: A curve showing the negative log-likelihood as a function of TD50. The curve 
graphically illustrates how 95% confidence intervals are determined and the non 
symmetric shape of log-likelihood plot. 
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had a greater MLD than patients who did not develop radiation pneumonitis. Other 
studies, such as those by Yorke et al (34) and Graham et al (30) concluded that the rate of 
radiation pneumonitis was significantly correlated to V20. Graham et al (30) analyzed the 
dose volume data for 99 patients treated definitively for NSCLC and reported that V20 
was significantly associated with the probability of developing radiation pneumonitis. 
Yorke et al (34) used 78 patients from a Phase I dose escalation study and reported that 
ipsilateral lung V20 was amongst one of the significant variables correlated with radiation 
pneumonitis. It is important to note that the literature also suggests that within individual 
datasets the dose-volume parameters are often correlated with one another (6, 20, 34). 
In addition to dose-volume parameters, researchers have attempted to identify 
clinical and patient factors that could help predict for the rate of radiation pneumonitis. 
Some of the factors include: the use of chemotherapy (35), performance status (36), 
smoking status (37), genetic information (38), tumor location within the lung (32, 33, 39), 
and functional status of the lung (40-42). In the lung literature survey, Marks et al (6) 
report inconclusive results relating the risk of radiation pneumonitis and surgery. Another 
controversial treatment factor that has been investigated is the use of chemotherapy. 
Many chemotherapy agents are known to cause pulmonary toxicities and perhaps 
exacerbate radiation induced lung injury.  In fact, from clinical experience, many 
physicians believe that chemotherapy increases the chance of developing radiation 
pneumonitis. However, this result has not been proven in the literature. For example, 
Graham et al (30), in their univariate analyses, did not find the use of chemotherapy to be 
significantly associated with the risk of developing radiation pneumonitis. Similarly, 
Robnette et al (36) did not find the use of chemotherapy to be predictive of radiation 
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pneumonitis. In the same study, Robnette et al (36) did find a correlation between 
performance status and radiation pneumonitis. Yuan et al (38) reported that certain 
genotypes were associated with a lower risk of radiation pneumonitis in NSCLC patients. 
Tumor location within the lung has also been studied as a potential factor associated with 
radiation pneumonitis. Hope et al (33) found that inferior tumor position was highly 
correlated with pneumonitis events while Robnette et al (36) did not find a similar 
pattern. Several studies have suggested that incorporating lung function into predictive 
models can improve the ability to predict for radiation pneumonitis (42). However, these 
are largely methodology and proof of concept studies (43). Overall many patient and 
clinical factors have been investigated in an attempt to improve the predictive power of 
radiation pneumonitis dose response models; however, the literature remains inconsistent 
and inconclusive (6, 7).  
Dose escalation trials using mathematical radiation pneumonitis models 
Several groups have used predictive mathematical models to guide dose escalation 
trials for NSCLC patients (4, 16, 44-47). The main idea in all of these trials was to use 
individual patient lung dose volume parameters to guide the tumor dose. The tumor dose 
was escalated until the lung dose volume constraints were met. For example, Bradley et al 
(16), set lung V20 limits while escalating the tumor dose. They reported that the dose was 
safely escalated using 3D-CRT to 83.9 Gy for patients with V20 values <25%, and to 77.4 
Gy for patients with V20 values between 25% and 36%. The group reported that elective 
nodal failure occurred in less than 10% of all patients. Other studies (46, 47) used the 
MLD to determine achievable tumor dose. Belderbos et al (46) escalated the prescription 
dose based on MLD. They reported that dose escalation was safe up to 94.5 Gy in 42 
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fractions in patients with MLD < 13.6 Gy. They also reported that they found higher 
doses were associated with better overall survival for smaller tumor volumes. Baardwijk 
et al (48) used a MLD of 19 Gy and a maximum spinal cord dose of 54 Gy to escalate 
tumor dose. They reported that their prescribed dose was 64.8 ± 11.4 Gy with a severe 
pneumonitis rate (grade 3 or higher) of 21%. A few studies went a step further (4, 44) and 
explicitly used NTCP models to determine dose volume constraints that yielded an 
acceptable complication probability. Kong et al (4) escalated dose based on the LKB 
NTCP model. Using the model, they binned patients into different bins according to the 
effective volume Veff. The group defined Veff as the volume of normal lung that would 
have to be uniformly irradiated to a given reference dose to result in a similar predicted 
level of radiation pneumonitis (4).  Overall the group was able to deliver doses ranging 
from 63 Gy to 103 Gy in 2.1 Gy fractions. The study reported survival of 4%, 22%, and 
28%, for patients receiving 63-69, 74-84, and 92-103 Gy, respectively. Overall, these 
results were promising and demonstrate that higher radiation doses can improve overall 
survival. Currently, the practice is to prescribe 60 to 70 Gy to the target for NSCLC 
patients. All of the dose escalation studies achieved target doses that are higher than those 
routinely given in the clinic. The local control and overall survival results were also 
promising. Although these studies represent a step in the right direction, it is important to 
point out that the models were entirely based on basic dose volume constraints. 
Incorporating other, non-dosimetric factors into the model could potentially increase the 
accuracy and utility of the model and enable further stratification of patients.  
Virtual dose escalation trials  
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 It is also possible to conduct virtual dose escalation trials where the theoretical 
gains in tumor dose can be assessed without the risk of harming patients. Baardfwijk et al 
(49) performed a dose escalation trial for 65 NSCLC patients. The group determined an 
individual maximal tolerable dose based on dose volume constraints for the lung and 
spinal cord. They found that an increase of 5.6% tumor control probability (TCP) could 
be gained by using the maximum tolerable dose determined by lung and spinal cord dose 
volume constraints. The group progressed the idea of the virtual trial and performed a 
prospective feasibility study (50). The study reports that the mean delivered dose was 
63.0 ± 9.8 Gy with mild acute lung toxicity rates (1 patient experienced grade 3 
pneumonitis). Mackay et al (51) performed a virtual study by prescribing patient dose 
based on cellular radiosensitivity. The group simulated varying patient radiosensitivties 
based on measured distributions among cancer patients of the surviving fractions of their 
fibroblasts given a dose of 2 Gy. They determined that their model showed that 
improvements in tumor control rates may be achievable through individualizing 
radiotherapy dose prescriptions.  
Patient database 
One of the largest NSCLC patient databases is collected at MD Anderson Cancer 
Center and is described in detail by Jin et al (37). The database includes 576 NSCLC 
patients that were treated with definitive radiation therapy at MD Anderson from 1999-
2005. Patients were treated with either 3D-CRT or IMRT. The database contains patients 
that were treated with and without chemotherapy. Patients were excluded from the study 
if their total dose was <50.4 Gy (which is considered a palliative dose), if they had doses 
per fraction that varied over the course of treatment, or had treatment breaks totaling >7 
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days.  The database includes clinical, dosimetric, demographic, chemotherapy, and 
outcome information. Some specific examples of the recorded information include: dose 
volume parameters for the lung, tumor stage and histology, smoking status, pulmonary 
function test (PFT) data, nodal status, and fractionation scheme. Radiation pneumonitis 
toxicity was scored by a physician on the basis of clinical presentation and radiographic 
abnormalities according to the National Cancer Institute’s CTCAE version 3.0 (18). The 
clinically significant end point used for the analysis was severe (grades 3-5) radiation 
pneumonitis. Grade 3 radiation pneumonitis is defined as severe symptoms, interfering 
with activates of daily living, and oxygen indicated. Grade 4 radiation pneumonitis is 
defined as life-threatening respiratory compromise and Grade 5 is death due to radiation 
pneumonitis. This retrospective study was approved by the Institutional Review Board at 
MD Anderson. 
 In the initial clinical analysis of the data, using univariate analyses, patient 
smoking status was the single factor most correlated with radiation pneumonitis. Other 
factors correlated with a lower rate of radiation pneumonitis include negative nodal 
status, use of 4-dimensional computed tomography (4DCT) simulation, and treatment 
with IMRT (37). Jin et al (37) also identified a DVH curve defined by V20 ≤ 25%, V25 ≤ 
20%, V35 ≤ 15%, and V50 ≤ 10%. In multivariate analysis, smoking status retained 
significance independent of dose-volume factors (37). Non-smokers were found to have 
the highest risk for radiation pneumonitis while smokers were found to have the lowest 
risk for toxicity. Tucker et al (52) found that the volume parameter (n) was not 
significantly different from 1, indicating that MLD can be used to predict for radiation 
pneumonitis. Tucker et al (52) also presented an NTCP model that included patient 
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smoking status and follow up time. The follow up time was included to account for 
patients that are censored by incomplete follow-up for any reason (including death) and 
takes into consideration patients who would eventually experience toxicity with 
sufficiently long follow-up. In other analysis of MD Anderson data, Yuan et al (38) found 
that certain genotypic expression of Single Nucleotide Polymorphisms (SNP) were 
associated with a lower risk of radiation pneumonitis.  
Purpose 
Studies have shown that dose escalation can lead to improved tumor control and 
subsequently better overall survival for NSCLC patients. However, lung dose is limited 
by normal tissue toxicity; mainly radiation pneumonitis. If we were able to more 
accurately predict for radiation pneumonitis, we could further personalize radiation 
treatment by prescribing a target dose that is tailored to the individual’s risk of 
developing radiation toxicity. Currently, prediction models rely on basic indices derived 
from the DVH and therefore are too simplistic and not yet accurate enough to be used to 
individualize tumor doses. Therefore, the purpose of this study will be to improve the 
accuracy of predictive risk models for radiation pneumonitis and to show the dosimetric 
benefit of using the models to guide patient treatment planning. The first part of the study 
will aim to improve the accuracy of radiation pneumonitis dose response models by 
incorporating spatial and functional aspects into the model. The second part of the study 
will use a dose response model in a virtual dose prescription trial to determine the 
potential dosimetric benefit of using a model to determine target dose. 
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Central hypothesis 
The fit of radiation pneumonitis dose response models can be significantly 
improved by incorporating information about the heterogeneous function of the lung. 
Specific Aims 
1. To incorporate the spatial location of dose within the lung into the modeling of 
radiation pneumonitis. 
Working hypothesis: The accuracy of radiation pneumonitis dose response models 
can be significantly improved by incorporating information about the spatial 
location of dose within the lung. 
2. To incorporate ventilation-based functional information into the modeling of 
radiation pneumonitis. 
Working hypothesis: The accuracy of radiation pneumonitis dose response models 
can be significantly improved by incorporating ventilation based functional 
information. 
3. To determine the potential benefit of using radiation pneumonitis modeling to 
optimize target dose for individual patients. 
Working hypothesis: The relative median difference in prescription dose between 
the model-generated plans and the clinically used plans will be greater than 5 Gy.  
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Specific Aim 1: Spatial Study 
Introduction 
 Current models describing the risk of developing radiation pneumonitis are based 
on dosimetric indices derived from the DVH. As an example, the MLD and V20 are 
metrics that are often used to predict for toxicity (30, 31). By definition, the DVH is a 
reduction of the 3D spatial dose distribution into the 2D domain. A single metric, such as 
MLD or V20, is an even further simplification of the 2D data. One consequence of the 
simplification of the 3D data into a single metric is a loss of spatial information. Spatial 
information is important because several researchers have proposed that lung function is 
not homogenous and may vary spatially throughout the lung. Specifically, studies have 
suggested that patients who get radiation therapy to the base of the lung are more likely to 
develop radiation pneumonitis than patients who get radiation to the apex of the lung (30, 
32-34, 39, 43, 53). Liao et al (39) irradiated mouse lung and determined that the base of 
the lung is more radiosensitive than the apex. In human studies, this data has been echoed 
by Yorke et al (32), who calculated various dosimetric indices for different portions of the 
lung. They found that that the mean dose to the inferior lung was highly correlated to 
radiation pneumonitis. Hope et al (33) and Bradley et al (53) analyzed the spatial location 
of GTV centroids and determined that inferior tumor position was indicative of higher 
rates of radiation pneumonitis. On the other hand, Robnette et al (36) did not find a 
relationship between dose to the lower lung and higher radiation pneumonitis rates. 
Overall, the data are inconclusive. Furthermore, the previously reported methods have 
limitations. Several authors note that there is a paucity of events in the lower portion of 
the lung, making the data unstable in the inferior lobes (33, 54). Many studies have made 
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conclusions using the GTV centroid to analyze the spatial effect.  However, using the 
GTV centroid is not ideal because the GTV centroid acts as a surrogate for the deposited 
dose and does not take into account factors such as the volume of the GTV or treatment 
planning tendencies and techniques. Another issue arises when researchers analyze GTV 
centroid or dose-volume data by dividing the lung into various geometrical regions. The 
results of analyzing the date by dividing the lung into regions are sensitive to the location 
of the boundaries that define the lung divisions. A more rigorous approach is needed to 
study the relationship between the spatial location of the deposited dose and radiation 
pneumonitis rates. Therefore, the purpose of this study is to develop a novel method to 
incorporate the spatial effect into radiation pneumonitis dose response models and to 
apply the method to the MD Anderson clinical NSCLC patient database to determine if 
there is a correlation between location and pneumonitis rates. Our hypothesis is that 
incorporating spatial information will statistically improve the fit of the predictive model. 
The study will be performed in 2 portions. In the first part of the study we will perform 
the analysis using GTV centroid information (54) and in the second portion we will 
incorporate the entire 3D dose distribution (55).  
GTV Centroid analysis 
Methods 
For this study we used 547 patients from the MD Anderson NSCLC patient 
database described in the introduction. The methods of the GTV centroid analysis are 
described in detail by Vinogradskiy et al (54). The first step is to de-archive each 
patient’s treatment plan into the treatment planning system (Pinnacle3, Philips Medical 
Systems, Milpitas, CA). Because, there are several unused treatment plans for each 
20 
 
patient, the clinically used plan needed to be correctly identified. This was done by cross 
referencing treatment planning parameters (prescription, number of beams, beam angles, 
monitor units) with the record and verify system and the patient’s paper chart. The rest of 
this chapter is taken from Vinogradskiy et al (54). 
“ GTV centroid analysis 
 The treatment plans for all 547 patients were de-archived into the 
treatment planning system and the GTV centroid of each patient was mapped onto 
one common coordinate system similar to the manner described by Hope et al. 
(33). The boundaries of the coordinate system were defined by the extreme points 
of each individual patient lung (Figure 2). Once all of the centroids were mapped 
onto the  
 
Figure 2: Schematic showing the mapping of GTV centroids from the treatment planning 
system (A) to the common coordinate system (B). The rectangles surrounding each lung 
indicate the extreme lung points that were used as boundaries to define the common 
coordinate system shown in (B). Printed with permission (54). 
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common coordinate system, the results were qualitatively analyzed by graphing 
the data in a coronal orientation. The data were graphed and displayed according 
to disease stage, smoking status, and the presence of severe pneumonitis. To 
further analyze the results, we binned the data into equal geometrical regions and 
used a chi-square test to determine whether there were statistically significant 
differences between the pneumonitis rates in the various lung regions. In order to 
further stratify the analysis according to disease stage, pneumonitis rates were 
calculated for a smaller cohort of patients with stage I and II disease and for 
another cohort of patients with stage III and IV disease. 
Modeling methods 
 We used the LKB model (24) with the volume parameter (n) set equal to 
one (52) to calculate NTCP for radiation pneumonitis…The model described in 
Eq. 4 represents the conventional dose-volume model incorporating MLD and was 
used as the baseline for statistical comparison with a second model that 
incorporated GTV centroid location. 
 To incorporate GTV centroid location into the predictive model we 
replaced the quantity t (in Eq. 4) with 
,  Equation 7 
where C is a model-fitting parameter and L is the GTV centroid coordinate. The 
quantity exp(CL) can be thought of as a dose modification factor (DMF) on TD50 
and has been proposed (52, 56) as a way to introduce risk-factors into the NTCP 
model. Six different orientations were investigated for the GTV centroid 
coordinate (L in Eq. 7): superior-inferior (SI), right-left (RL), anterior-posterior 
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(AP), medial-lateral (ML), radial, and SI distance from the mean SI position of all 
GTV centroids. The radial coordinate was taken as the radial distance from the 
center point of the medial edge of each lung box. Anatomically, this coordinate is 
analogous to the radial distance from the center point of the mediastinum. Using 
maximum likelihood analysis and the likelihood-ratio test, we compared the 
model that incorporated GTV centroid information and dose-volume information 
(Eq. 7) to the baseline dose-volume model (Eq. 4) to determine whether adding 
GTV centroid information significantly improved the fit of the model.  
In addition to comparing the GTV centroid location model to the basic 
dose-volume model, a comparison was made using our best fitting model to date, 
which currently incorporates dose-volume information, smoking status, and 
follow-up time (52). Mathematically, smoking status is incorporated into the 
model by introducing covariate DMFs that account for smoking status (52). The 
follow-up time accounts for patients that are censored by incomplete follow-up for 
any reason (including death) and takes into consideration patients who would 
eventually experience toxicity with sufficiently long follow-up. The likelihood-
ratio test was used to compare our current, most accurate model (which 
incorporated dose-volume, smoking status, and follow-up time) versus the same 
model with the GTV centroid DMF added in. All statistical work was done with 
MATLAB software. 
Analysis of GTV centroids that exclude nodal volume 
Seventy five percent of the patients in our database had stage III or higher 
disease, which indicates nodal involvement. The practice in our clinic (and the 
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method used for this study) is to contour the primary tumor and nodal volume and 
consider that area the GTV. Therefore, the centroids calculated for this analysis 
included the primary tumor as well as the nodal volume. The other possibility for 
performing this type of analysis is to exclude the nodal volume when calculating 
the centroid of the GTV. There are advantages and disadvantages to both 
methods. For example, excluding the nodal disease in the centroid calculation has 
the advantage of better isolating the spatial location of the primary tumor in the 
lung parenchyma. On the other hand, including the nodal volume provides a GTV 
centroid that is a better representation of the true location of the deposited dose. In 
order to determine whether including nodal volume made a difference in our 
results we re-contoured the GTV of every patient to exclude nodal volume, re-
analyzed the data, and compared the results to the results obtained while including 
the nodal volume in the GTV centroid calculation.  
Results 
Qualitative GTV centroid results 
 Of the 547 patients analyzed, 111 (20.3%) experienced severe radiation 
pneumonitis. Figure 3 shows a coronal view of all GTV centroids. The mean SI 
position of all tumors was located at 0.62 on a scale of 0 to 1 (0 corresponding to 
the inferior end and 1 corresponding to the superior end). Graphing of GTV 
centroid location according to tumor stage (Figure 4) indicated that the GTV 
centroid of patients with Stage III and IV disease appeared to be 
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Figure 4: Coronal view of all GTV centroids displayed according to tumor stage. 
Printed with permission (54). 
 
 
 
Figure 3: Coronal view of 
all GTV centroids (A) 
displayed according to the 
presence of severe 
pneumonitis. The coronal 
CT slice (B) is shown to 
indicate the orientation of 
the GTV centroid plot. 
Printed with permission 
(54). 
. 
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concentrated toward the middle of the grid, which anatomically correlates to the 
mediastinum, while the GTV centroids of patients with Stage I and II disease were 
scattered toward the periphery of the lung. The average ML GTV centroid 
position of patients with stage I and II disease was 0.49 while the average ML 
GTV centroid position of patients with stage III and IV disease was 0.34 (where 0 
is defined as the medial border and 1 is defined as the lateral border). The 
difference in ML GTV centroid position between the two groups is significantly 
different (p < 0.001 as calculated by the Wilcoxon rank-sum test). The overall 
spatial pattern of the GTV centroid location for patients with and without 
pneumonitis appeared to be similar in the cohort of patients with stage I and II 
disease (Figure 5) and the cohort of patients with stage III and IV disease (Figure 
5). In addition, GTV centroids were stratified by patient smoking status (Figure 
6). Qualitatively, the GTV centroids of non smokers are notably absent from the 
superior region of the lung. The average SI GTV centroid position of non smokers 
is 0.58 (range of 0.23-0.81) while the average SI GTV centroid position for 
smokers and former smokers is 0.62 (range of 0.10-1.00). However, the difference 
in SI GTV centroid position between the non smokers and former and current 
smokers was not significant ( p = 0.172 as calculated by the Wilcoxon rank-sum 
test).  
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Figure 6: Coronal view of all GTV centroids displayed according to smoking status.  
Printed with permission (54). 
Figure 5: Coronal view of GTV centroids displayed according the presence of severe 
pneumonitis for patients who had stage I and II disease (A) and patients who had stage 
III and IV disease (B). Printed with permission (54). 
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Figure 7 shows a graphical comparison of the GTV centroids that included 
nodal volume (Figure 7A) and GTV centroids where nodal volume was excluded 
(Figure 7B). As expected, when nodal volume is excluded, the density of  
 
the GTV centroids appears to move toward the periphery of the lung away from 
the mediastinum. However, the severe pneumonitis events appear to have the 
same spatial distribution whether nodal volume is included or excluded.  
Pneumonitis Rates 
Our study cohort included 325 right-lung tumors and 222 left-lung tumors. 
The severe pneumonitis rate was 22.5% (73/325) for the right-lung tumors and 
17.1% (38/222) in the left- lung tumors. Table 2 shows the pneumonitis rates 
when the lungs are divided into equal thirds in the SI orientation. The pneumonitis 
Figure 7: Coronal view of GTV centroids displayed according to the presence of severe 
pneumonitis when nodal volume is included in the GTV centroid calculation (A) and when 
nodal volume is excluded in the centroid calculation (B). Printed with permission (54). 
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rate was lowest in the superior portion of the lung (16%); however, the 
pneumonitis rates were not significantly different (p=0.376 using the chi-square 
test). Table 3 shows the pneumonitis rates when the lung was divided into equal 
quartiles. 
SI Location 
(scale 0-1) 
Pneumonitis rate 
Superior 
(0.66-1) 0.16 (35/218) 
Middle  
(0.33-0.66) 0.23 (70/301) 
Inferior 
(0-0.33) 0.21 (6/28) 
 
 
SI Location 
(scale 0-1) Pneumonitis rate 
Superior 
(0.75-1) 0.11 (11/100) 
Upper Middle 
(0.5-0.75) 0.23 (76/327) 
Lower Middle 
(0.25-05) 0.21 (22/105) 
Inferior 
(0-0.25) 0.13 (2/15) 
 The pneumonitis rate was lowest in the upper quartile (11%); again, however, the 
pneumonitis rates were not significantly different (p=0.056). It should also be 
noted that the most inferior quartile displayed a low pneumonitis rate (13%); 
however, the number of patients with centroids in this region is small, so the 
pneumonitis rate is subject to uncertainty (2 pneumonitis events out of 15 total 
Table 3. Pneumonitis rates for each superior-inferior quartile of the lung. 
Printed with permission (54). 
 
Table 2. Pneumonitis rates for each superior-inferior third of the lung. Printed 
with permission (54). 
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Table 4. Pneumonitis rates according to quartiles with the two inferior 
quartiles combined. Printed with permission (54). 
 
centroids). Because of the paucity of events in the lower quartile the data for the 
bottom two quartiles were combined (Table 4). We calculated pneumonitis rates 
of 11%, 23%, and 20% for the upper quartile, middle quartile, and lower two 
quartiles, respectively. 
SI Location 
Pneumonitis 
rate 
Superior 
(0.75-1) 0.11 (11/100) 
Middle  
(0.5-0.75) 0.23 (76/327) 
Inferior 
 (0-0.5) 0.20 (24/120) 
 
In order to compare our data with prior literature we stratified our data according 
to lobe. Specifically, we set the upper lobe equal to the upper half of the left lung 
and upper third of the right lung and the lower and middle lobe aggregate equal to 
the lower half of the left lung and the lower two-thirds of the right lung.  Dividing 
the data in such a manner yielded pneumonitis rates of 18% for the upper lobes 
and 24% for the middle and lower lobes. Table 5 shows the pneumonitis rates 
when the data is further isolated to a smaller cohort of patients with stage I and II 
disease and another cohort of patients with stage III and IV disease. The 
pneumonitis rates for stage I and II patients were similar for all 3 regions. The 
penumotnies rates were 18%, 17%, and 20% for the  superior, middle, and inferior 
regions respecitvely. The pneumonitis rate for stage III and IV patients was lower 
for the superior portion (15%) than for the middle (25%) or the inferior portions 
(22%). 
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Table 6. Pneumonitis rates for each superior-inferior third of the lung when 
nodal volume is excluded from the GTV centroid calculation. Printed with 
permission (54). 
 
 
Table 5. Pneumonitis rates divided into thirds for patients grouped according 
to disease stage. Printed with permission (54). 
 
 
 
 
 
 
 
 
 
Table 6 shows the pneumonitis rates when the lung is divided into SI 
thirds for the GTV centroids that excluded the nodal volume. The pneumonitis 
rates were 15%, 25%, and 19% for the superior, middle, and inferior portions of 
the lung respectively. These numbers are similar to what was reported for the 
GTV centroids that included the nodal volume (Table 2). 
SI Location 
(scale 0-1) 
Pneumonitis rate 
Superior 
(0.66-1) 0.15 (32/218) 
Middle  
(0.33-0.66) 0.25 (72/293) 
Inferior 
(0-0.33) 0.19 (7/36) 
 
 
 
 
 
SI Location 
(scale 0-1) 
Pneumonitis rate for 
stage I + II patients 
Pneumonitis rate for 
stage III + IV patients 
Superior 
(0.66-1) 0.18 (7/39) 0.15 (28/181) 
Middle  
(0.33-0.66) 0.17 (10/60) 0.25 (62/239) 
Inferior 
(0-0.33) 0.20 (2/10) 0.22 (4/18) 
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Table 7. Statistical comparison of nominal dose-volume model with modified (to include 
GTV centroid information) dose volume models according to modeling parameters and 
corresponding p values. Abbreviations: GTV = gross tumor volume, MLD = mean lung 
dose; CI = 95% confidence intervals, DMF = dose modification factor; SI = superior-
inferior, AP = anterior-posterior, ML = medial-lateral, RL = right-left. Printed with 
permission (54). 
 
 
 
Modeling results 
Table 7 shows the modeling parameters, 95% confidence intervals, and 
significance results. The comparison of the GTV centroid model and the 
conventional dose-volume model did not yield a statistically significant difference 
in model fit for the various orientations in GTV centroid spatial location that were 
investigated (all p values greater than 0.146). It should also be noted that when 
modeling parameters listed in Table 6 were recalculated for the GTV centroids 
that excluded the nodal volume, all of the p values remained above 0.05 indicating 
that including GTV centroid information does not improve the fit of the model to 
the data. Furthermore, Table 7 illustrates that incorporating GTV centroid 
information did not increase the predictive power of our current best-fitting model 
(all p values greater than 0.259). 
Model parameters TD50 (CI) m (CI) DMF (CI) p 
MLD 33.8 (29.1 43.1) 0.471 (0.37 0.63) 1.000 --- 
MLD + SI Location 32.4 (24.9 49.9) 0.467 (0.37 0.63) 1.096 (0.55 2.01) 0.766 
MLD + AP Location 40.8 (27.4 73.9) 0.469 (0.37 0.63) 0.717 (0.32 1.45) 0.341 
MLD + ML Location 34.2 (26.8 49.7) 0.470 (0.37 0.63) 0.967 (0.49 2.01) 0.920 
MLD + RL Location 30.9(24.5 42.5) 0.476 (0.37 0.64) 1.246 (0.75 2.50) 0.400 
MLD + Radial Location 35.0 (27.2 51.4) 0.469 (0.37 0.63) 0.897 (0.42 2.03) 0.768 
MLD + SI distance 
from mean SI position 
31.4 (27.2 39.9) 0.482 (0.38 0.66) 2.185 (0.78 13.97) 0.146 
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Table 8. Statistical comparison of most accurate current model with most 
accurate model modified by GTV centroid location. Abbreviations: MLD = 
mean lung dose; SI = superior-inferior, AP = anterior-posterior, ML = medial-
lateral, RL = right-left. Printed with permission (54). 
 
 
 
 
 
Model parameters p 
MLD + Smoking  
+ Time Censored NA 
MLD + Smoking  
+ Time Censored + SI Location 
0.802 
MLD + Smoking  
+ Time Censored + AP Location 
0.301 
MLD + Smoking  
+ Time Censored + ML Location 
0.893 
MLD + Smoking  
+ Time Censored + RL Location 
0.259 
MLD + Smoking  
+ Time Censored + Radial Location 
0.748 
MLD + Smoking +  
+ Time Censored + SI distance from SI mean 
0.796 
 
 
 
 
Discussion 
 The GTV centroid mapping performed in this study was done in a similar 
manner to the methods used by Hope et al. (33) and Bradley et al. (16), who 
divided the lung into quartiles and combined the two most inferior quartiles to 
account for the paucity of pneumonitis events. Hope et al. (33) reported grade 2 
(steroids given for clinically significant pulmonary symptoms) pneumonitis rates 
of 9%, 25%, 35% for the upper quartile, middle quartile, and lower two quartiles, 
respectively while Bradley et al. (16) reported 4%, 25%, and 35%, for the upper 
quartile, middle quartile, and lower two quartiles, respectively. When we divided 
our data in a similar manner, we calculated pneumonitis rates of 11%, 23%, and 
20% for the upper quartile, middle quartile, and lower two quartiles, respectively. 
The pneumonitis rates from the two studies show good agreement in the upper 
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two quartiles. However, our results did not show increasing pneumonitis rates 
toward the inferior of the lung, as indicated in the study by Hope et al. (33) and 
Bradley et al. (16). It is also possible to compare our data with results presented 
by Graham et al. (30), who categorized tumor location by lobes and reported 
pneumonitis rates of 11% for the upper lobe and 29% for the middle and lower 
lobes. Dividing our data according to lobe yielded pneumonitis rates of 18% for 
the upper lobes and 24% for the middle and lower lobes. The lower pneumonitis 
rate in the upper lobe was reproduced; however, the difference in pneumonitis 
rates between the lobes was not as extreme as that presented by Graham et al. 
(30). One possible explanation for the discrepancy between the results of our 
study and those of the studies by Hope et al. (33), Bradley et al. (16) and Graham 
et al. (30) is the limited incidence of GTV centroids near the inferior region of the 
lung. Our study and the study by Hope et al. (33) both noted paucity of centroids 
and events in the inferior portion of the lung, which implies that pneumonitis rates 
can be erratically driven by the presence or absence of a few events.  
 The modeling results and the data presented in Figure 7 and Table 6 
indicate that there is little difference when comparing GTV centroids that include 
nodal volume and GTV centroids that exclude nodal volume. Theoretically, there 
are advantages and disadvantages to using either method; however, our results 
indicate that the inclusion or exclusion of the nodal volume in the GTV centroid 
calculation does not influence the relationship between spatial location and 
pneumonitis rates.  
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 Figure 6 illustrates that GTV centroids located in the superior portion of 
the lung were associated with smokers and former smokers. The superior portion 
of the lung also showed the lowest pneumonitis rates (Tables 2-4).  Several 
studies have noted that the risk of developing radiation pneumonitis is influenced 
by smoking status (37, 52, 57, 58). Our results indicate that smoking status also 
influences the spatial position of the tumor within the lung. This indication may 
help explain why lower pneumonitis rates have been observed in the superior 
region of the lung (32, 33, 53). 
Despite our large patient population, we were not able to significantly 
improve the accuracy of the pneumonitis model by incorporating GTV centroid 
information. This finding conflicts with other studies, which have reported a 
correlation between pneumonitis and radiation to the lower lung.  One possible 
explanation is the noted (32, 33) paucity of events in the lower lung. Another 
potential reason for the discrepancy is that we investigated GTV centroids, while 
Yorke et al. (32) and Seppenwoolde et al (43) analyzed dose metrics for various 
regions of the lung.  
The methods and data presented in this work builds on prior studies and 
offers some unique advantages to performing a spatial analysis. This study is done 
with a large clinical database of 547 patients, which affords it greater statistical 
power. In addition, the method of including GTV centroid location as a DMF in 
the predictive model is a rigorous way to analyze the spatial effect because it 
explicitly aims to separate the dose volume parameter and the spatial parameter. 
Furthermore, the presented modeling method treats GTV centroid location as a 
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continuous variable and is therefore not dependant on the location of the lung 
division (as is the case when dividing the lung into various regions and calculating 
pneumonitis rates). Finally, the data presented in this work studies the relationship 
between GTV centroid location and smoking status, disease stage, and whether or 
not including nodal volume influences spatial results” (54). 
3D Dose Spatial Analysis 
Methods 
The 3D spatial analysis was performed using the same patient database described in the 
introduction. The study was published by Vinogradskiy et al (55) and is quoted here. 
“Novel Spatial Analysis 
All patient treatment plans were de-archived into the treatment planning 
system and the 3D dose distribution of each patient lung was mapped onto one 
common coordinate system. The boundaries of the coordinate system were 
defined by the extreme points of each individual patient lung (Figure 8). For each 
patient, the  
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coordinate system for the right and left lungs were determined separately. For 
example, the extreme medial point of the right lung provided the medial boundary 
of the right lung coordinate system while the extreme lateral point of the right 
lung provided the lateral boundary of the right lung coordinate system. The 
boundaries were defined in the same manner for the anterior-posterior (AP) and 
superior-inferior (SI) orientations. The end result was a 3D matrix for each lung 
that contained the dose distribution inside that lung and was defined from 0 to 1 in 
each orientation. The 3D matrix was a masked image of the dose inside the lung, 
in other words, each pixel contained a scaled dose value if it was within the lung 
and 0 if the pixel was outside of the lung contour. This process ensured that each 
Figure 8: An example of dose from two coronal planes (intended to represent a 3D dose 
distribution) mapped from the treatment planning system (A) to the common coordinate 
system (B). The common coordinate system for each lung is defined by the extreme 
boundaries of that particular lung. The boundaries for the left and right lung are defined 
separately. As an example, a rectangle highlights the extreme points of the right lung in the 
superior, inferior, medial, and lateral orientations (A). The result is a 3D matrix (B) for 
each lung that contains the dose distribution inside that lung and is defined from 0 to 1 in 
each orientation. Printed with permission (55). 
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patient’s lung dose distribution was defined from 0 to 1 and was therefore mapped 
on the same coordinate system. It should be noted that the lung region of interest 
(ROI) was defined as total lung minus GTV.   
Once all dose distributions were mapped onto the common coordinate 
system the spatial information was incorporated into a predictive radiation 
pneumonitis model. To be consistent with the literature, we used the LKB 
formulation (24) to calculate NTCP…To incorporate spatial information into the 
LKB model, the dose to each voxel was weighted according to its location in the 
lung. We started with the mathematical definition of MLD which can be written as 
, Equation 8 
where v is the volume, D is the dose, and i loops over all the dose bins. Next, we 
modified the term in Equation 8 to define a spatially weighted effective dose that 
can be written as  
. Equation 9 
Substituting the new effective dose term (Eq 9) and re-writing the parameter t (Eq 
4) the new model can be written as  
 Equation 10 
where C is a model fitting parameter and w is a spatial weighting value that comes 
from a user-defined spatial weighting matrix. The user-defined spatial weighting 
matrix is intended to reflect the spatial pattern that is to be investigated. For this 
work, we investigated spatial weighting matrices that contained linearly scaled 
values between 0 and 1 according to each of the following orientations: SI, AP, 
right-left (RL), medial-lateral (ML), and radial. Conceptually, the higher 
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weighting values imply that a particular region is more radiosensitive than the 
region described by the lower weighted values. As an example, an SI weighting 
matrix (Figure 9A) assumes that the dose to the superior lung voxels is less lethal 
than the dose to the inferior lung voxels while a radial weighting matrix (Figure 
9B) assumes the dose to the periphery of the lung is more lethal than the dose 
closer to the mediastinum.  
 
 
In addition to linear SI weighting, we investigated a ramp function weighting 
scheme. The ramp function weighting scheme originated from our previous GTV 
centroid analysis which found pneumonitis rates of 11%, 23%, and 20% for the 
superior, middle, and inferior portion of the lung respectively (54). The ramp 
function weighting scheme (Figure 9C) weighs the superior voxels by 0 and 
linearly increases the weighting towards 1 for the middle and inferior portions of 
the lung. The model fitting parameter C allows the relative contribution of the 
Figure 9: An example slice of a superior-inferior weighting scheme (A), a radial weighting 
scheme (B), and a ramp function weighting scheme (C). The CT images are included to 
indicate the orientation of the weighting slices. Printed with permission (55). 
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spatially weighted voxels to change based on the entire population. The sign of 
the parameter C provides information on whether the optimal fit of the model is 
along the direction of the weighting scheme chosen (positive C value) or against 
the direction of the weighting scheme chosen (negative C value). The TD50, m, 
and C parameters were all fit to our dataset. To test the significance of 
incorporating spatial information into the LKB model the likelihood ratio test was 
used. Specifically, the fit of the model that incorporated spatial and dose-volume 
information (Eq. 10) was compared to the fit of the dose volume model (Eq. 4) to 
determine whether adding spatial information significantly improved the fit of the 
model to the data. We present the significance value (p) that demonstrates whether 
or not there was a statistically significant improvement in the model fit. 
Lung Division Analysis 
As a byproduct of the lung-mapping method described in the previous 
section it is trivial to write computer code to divide the lung into various 
geometrical regions and study the correlation between local dosimetric parameters 
of each lung region and radiation pneumonitis rates. In order to compare our 
results with previous work, we divided the lungs according to volume into equal 
geometrical halves (superior and inferior half) and equal geometrical thirds 
(superior, middle, and inferior third). A mean dose was calculated for each local 
region.  A multivariate logistic regression analysis with stepwise inclusion of 
factors was used to determine which local mean dose was independently 
correlated with radiation pneumonitis.  Furthermore, we tested whether the mean 
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Table 9. A comparison of model parameters and significance values for the various 
weighting schemes investigated. Abbreviations: CI95 = 95% confidence intervals, CI68 = 
68% confidence intervals,  MLD = mean lung dose; SI = superior-inferior, AP = anterior-
posterior, ML = medial-lateral, inf = infinity, RL = right-left. Printed with permission (55). 
 
 
dose to any one particular region was a better predictor of radiation pneumonitis 
than the overall MLD. 
Results 
Of the 547 patients analyzed, 111 (20.3%) experienced severe (grade 3 or 
greater) radiation pneumonitis. Table 9 shows the model fitting parameters, 95% 
and 68% confidence intervals, and the p values for the various weighting schemes 
investigated.  
Model 
parameters 
Orientation of 
matrix 
TD50  
(CI95) 
(CI68)   
m  
(CI95) 
(CI68)   
C  
(CI95) 
(CI68) 
p 
MLD 
NA 34.6 
(30.1 45.3) 
(31.9 38.7 
0.488 
(0.38 0.67) 
(0.42 0.57) 
NA NA 
MLD + SI 
Weighting 
0 = superior 
1 = inferior 
29.8 
(19.2 99.2) 
(23.1 44.3) 
0.478 
(0.37 0.66) 
(0.41 0.56) 
-0.292 
(-0.99 3.46) 
(-0.72 0.54) 
0.6468 
MLD + AP 
Weighting 
0 = anterior 
1 = posterior 
27.0 
(14.00 732) 
(18.4 51.3) 
0.488 
(0.38 0.67) 
(0.43 0.57) 
-0.484 
(-1.36 41.5) 
(-1.05 1.01) 
0.6330 
MLD + ML 
Weighting 
0 = medial 
1 = lateral 
37.3 
(16.64 inf) 
(22.7 117.8) 
0.489 
(0.38 0.67) 
(0.42 0.57) 
0.160 
(-1.1103 inf) 
(-0.7 4.8) 
0.9034 
MLD + RL 
Weighting 
0 = right 
1 = left 
32.9 
(25.1 51.8) 
(28.3 39.9) 
0.491 
(0.38 0.67) 
(0.42 0.57) 
-0.123 
(-0.70 0.81) 
(-0.43 0.26) 
0.7189 
MLD + Radial 
Weighting 
0 = central 
1 = distal 
14.1 
(10.3 inf) 
(14.4 56.1) 
0.495 
(0.37 0.68) 
(0.42 0.58) 
-0.394 
(-1.44 inf) 
(-1.18 1.20) 
0.5742 
MLD + ramp 
function 
Weighting 
0 = superior 
1 = inferior 
21.1 
(11.3 inf) 
(14.5 41.6)  
0.470 
(0.36 0.65) 
(0.41 0.55) 
-0.418 
(-0.74 inf) 
(-0.63 0.20) 
0.4176 
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The comparison of the conventional dose volume model and the spatially 
weighted dose model did not yield a statistically significant difference in model fit 
for any of the spatial weighting schemes. These results suggest that taking 
individual voxel location into account does not significantly improve the fit of the 
model. 
When dividing the lung into two halves, both the mean dose to the 
superior half and the mean dose to the inferior half were associated with severe 
pneumonitis. In a stepwise logistic regression analysis, using the mean dose to the 
superior half, the mean dose to the inferior half, and the overall MLD, the overall 
MLD was selected at the 0.05 significance level. When dividing the lung in thirds, 
the mean dose to the middle third was the only dosimetric quantity associated 
with severe pneumonitis. It is also important to note that the log-likelihood using 
the overall MLD was greater than the log-likelihood using the middle region mean 
dose, indicating that the overall MLD was more accurate in predicting radiation 
pneumonitis than was the mean dose to the middle third. The scatter plot in Figure 
10 indicates that when the mean doses to the three regions (inferior, middle, and 
superior) were compared against the overall MLD, the mean dose to the middle 
lung region is most correlated with the overall MLD. 
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Discussion 
 The presented work proposes a novel method to study the relationship 
between the spatial location of the deposited 3D lung dose distribution and 
pneumonitis rates. The method proposed in this study builds on prior work and 
provides unique advantages to performing a spatial dose analysis. In previous 
work, there have been two general approaches to studying the relationship 
Figure 10: Scatter plots showing a comparison between the total mean lung dose and the 
superior region mean dose (A), middle region mean dose (B), and inferior region mean 
dose (C). The severe pneumonitis events are shown as red circles while the non 
pneumonitis events are displayed as black stars. Printed with permission (55). 
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between the spatial effect and pneumonitis rates. These approaches involve 
dividing the lung into various geometrical regions and studying the dosimetric 
indices derived from them (34, 43) or studying the GTV centroid locations (30, 
33, 53). As noted by Hope et al. (33), the GTV centroid acts as a surrogate for the 
location of the deposited dose and does not take into account GTV volume or 
treatment planning techniques. In addition, the results of both methods are 
sensitive to the location of the boundaries that define the lung divisions. The 
spatial weighting method proposed in this work incorporates the entire 3D dose 
distribution and treats each orientation as a continuous variable and therefore the 
results do not depend on how the lung is divided. Furthermore, after all the dose 
distributions have been mapped onto the common coordinate system, it is then 
possible to divide the data along any geometrical boundaries without the laborious 
process of re-contouring and re-calculating dosimetric parameters in the treatment 
planning system. In this work, we divided the lung into two and three equal-
volume superior-inferior regions. However, it would be a matter of a few lines of 
computer code to divide the dose distributions into any number of divisions along 
any orientations. Finally, incorporating the spatial dose information into the LKB 
model and testing for a statistically significant increase in model accuracy allows 
for a way to mathematically separate spatial location and dose volume effects. We 
believe this is a more rigorous approach to determining whether the spatial 
location of the deposited lung dose is correlated with pneumonitis rates. 
 When dividing our data in a similar manner to Yorke et al. (34) (into a 
superior and inferior region) we found that both regions were significantly 
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associated with radiation pneumonitis at the 0.05 significance level. While Yorke 
et al. (34) found that only dosimetric indices to the inferior lung region were 
associated with radiation pneumonitis. Both studies confirmed that dosimetric 
indices to the entire lung were correlated with pneumonitis. One possible 
explanation for the disagreement in the results to the superior lung region is the 
overall location of the deposited dose in the two study populations. When dividing 
the lung into three regions we found that only the middle region mean dose was 
associated with radiation pneumonitis and the scatter plot (Figure 10) confirmed 
that the overall MLD values are most closely resembled in the middle portion of 
the lung. Most of the patients in our database have clinical stage III or higher 
disease and the dose to the middle portion of the lung is a product of irradiating 
the nodes in the mediastinum. Therefore, the best representation of the overall 
MLD is the mean dose to the middle portion of the lung. It is also important to 
note that when dividing the lung into regions we found that the best predictor of 
pneumonitis was the overall MLD and not the mean dose to any one particular 
region confirming that for our data there is no additional benefit to analyzing 
different portions of the lung. 
 The modeling and lung division results indicate that for our patient cohort 
the spatial location of the deposited lung dose does not influence the risk of 
radiation pneumonitis. This finding is generally not in agreement with the other 
studies which indicate a relationship between dose to the inferior lung and 
pneumonitis rates (30, 33, 34, 53). For example, Hope et al. (33) report grade 2 
(steroids given) pneumonitis rates of 9% for the upper quartile of the lung, 25% 
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for the middle quartile, and 35% for the lower two quartiles and Bradley et al. 
(53) cite 4% for the upper quartile, 25% for the middle quartile, and 35% for the 
lower two quartiles. When we divide our data in a similar manner, we calculated 
pneumonitis rates of 11%, 23%, and 20% for the upper, middle, and lower two 
quartiles respectively (54). Comparing our data with the studies performed by 
Hope et al. (33) and Bradley et al., (53) there is good agreement in the upper two 
quartiles; however, our study does not show decreasing pneumonitis rates towards 
the inferior of the lung. There are several possible explanations for the differing 
results. One possible explanation is the difference in methods used to perform the 
analysis. The studies mentioned above analyzed GTV centroid location while the 
current study uses the 3D dose distribution. Another possible explanation for the 
discrepancy is the differing patient populations. As noted earlier, our study 
contains patients mostly with stage III and higher disease. As a result of 
irradiating the nodes in the mediastinum most of the dose is concentrated in the 
middle portion of the lung. Therefore, it is possible that most of the valuable 
dosimetric information is contained within the middle portion of the lung, over-
riding any superior-inferior spatial effect. Another possible explanation for the 
differing results is the lack of information towards the inferior portion of the lung. 
The Hope et al. (33) study and our study (54) both note a lack of centroids 
towards the inferior lung. The lack of centroids in the inferior lung implies that 
pneumonitis rates can be erratically driven the presence or absence of a few 
pneumonitis events.  
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 The novel method was applied to a patient database and it was determined 
that for our patient cohort the spatial location does not influence the risk of 
pneumonitis. Because of the number of patients in our study and the rigor of our 
novel spatial method we believe that the current work adds an important clinical 
contribution to existing knowledge about the spatial effect in the lung” (55). 
There were several limitations to our spatial analysis. We used the LKB MLD model to 
perform the modeling in this study. We chose this model because it is consistent with 
what has been cited in the literature (6) and consistent with the methods we previously 
used to analyze our data (37, 52). In future work, it would be interesting to incorporate 
spatial information into other mathematical forms of dose response models (26, 27) and 
test for whether the fit of the model is improved. In addition, as more patient data is 
collected, it would be informative to perform a 3D spatial analysis for patients grouped by 
their clinical stage to further isolate the spatial effect. 
Conclusions 
A novel method using the GTV centroid and the 3D spatial dose distribution was 
proposed to investigate the relationship between the location of the deposited lung dose 
and pneumonitis rates. The method provides unique advantages in that it: incorporates the 
entire 3D dose distribution, treats spatial information as a continuous variable, and aims 
to mathematically separate spatial and dose volume effects. The novel spatial method was 
applied to a large 547 NSCLC patient database. The hypothesis of this study is rejected; 
incorporating spatial information did not improve the fit of the model to the data. 
Although our results showed lower pneumonitis rates for the superior portion of the lung, 
we did not find an overall trend of increasing pneumonitis rates toward the inferior 
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portion of the lung. Furthermore, for our patient cohort, incorporating GTV centroid 
information or 3D spatial information did not lead to a statistically significant gain in 
pneumonitis model fit, indicating that for our patient cohort the spatial location of the 
deposited dose not influence the risk of pneumonitis (54, 55).  
Specific Aim 2: Ventilation study 
Introduction 
 For lung cancer patients, lung function may not be homogeneous and may vary 
throughout the lung. Lung function can be heterogeneous because of the tumor, prior 
existing lung conditions such as emphysema and chronic obstructive pulmonary disease 
(COPD), or the inherent heterogeneity of the lung parenchyma. Currently, NTCP models 
rely on basic dose-volume metrics (such as MLD and V20) and do not take into 
consideration the heterogeneous lung function. Several researchers have proposed to 
incorporate imaging to assess lung function and to predict for thoracic toxicity (40-43, 
59-62). Most of the studies have investigated either SPECT based perfusion imaging or 
CT imaging. Nioutsikou et al (42) and Miften et al (41) provide methodology on 
incorporating SPECT-based functional imaging into predictive modeling. Seppenwoolde 
et al (43) studied the regional lung differences using perfusion. Ma et al (63) reported a 
weak correlation between CT-based density changes and PFT results. However, besides 
CT and SPECT-based perfusion, few imaging modalities have been incorporated into the 
evaluation of normal tissue toxicity. One potential way to assess lung function is through 
ventilation. As noted by Vinogradskiy et al (64)… 
“An exciting and new form of ventilation imaging has been proposed by Guerrero 
et al. (65). These authors proposed to use 4-dimensional computed tomography 
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(4DCT) data to calculate ventilation. A 4DCT data set consists of 3-dimensional 
(3D) CT images resolved into different phases of the breathing cycle (66, 67). 
Because 4DCT data are routinely acquired for thoracic radiation therapy treatment 
planning, calculating ventilation maps from 4DCT data does not add any extra 
dosimetric or monetary cost to the patient. Several groups have investigated 
different aspects of ventilation imaging (44, 65, 68-71). For example, Yaremko et 
al. (59)
\
 discussed the idea of designing treatment plans to avoid highly ventilated 
areas of the lung, Ding et al. (72)
 
studied the changes in lung ventilation after 
radiation therapy, Castillo et al. (73) explored the different ways of calculating 
ventilation from 4DCT data with corresponding comparative evaluation with 
clinically acquired SPECT ventilation, and Yamamoto et al.
 
(69)
 
investigated 
4DCT based ventilation imaging for patients with emphysema” (64). 
The detailed methodology of calculating ventilation maps from 4DCT data is described in 
detail by Vinogradskiy et al (64). 
“The first step is to export all of the phases of the 4DCT dataset and 
appropriately segment both lungs on the exhale and exhale CT datasets. Lung 
segmentation was performed by delineating lung voxels with CT values from -999 
to -250 and by using a three-dimensional morphological growing algorithm
 
(73) to 
delineate the trachea, main-stem bronchi, and pulmonary vasculature” (64).  
An example axial and coronal slice of segmented lung is shown in Figure 11.  
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The remaining steps of calculating ventilation images are described by Vinogradskiy et al 
(64). 
“Once the lungs were segmented, deformable image registration using trajectory 
modeling (74) was used to link corresponding lung volume elements together 
between the inhale and the exhale data sets (Figure 12). It should be noted that 5 
phases (half of the breathing cycle) were used for the registration algorithm and 
the segmentation used for the registration algorithm was more coarse than the 
procedure used for the ventilation image segmentation. The spatial accuracy of the 
registration algorithm has been  
Figure 11: An example of segmented lung. The sagittal and axial planes are shown. It 
should be noted that the vasculature within the lung is excluded. 
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reported to be 1.25mm (74). Following spatial registration, corresponding 
Hounsfield units were input into a density-change-based model. The model can be 
mathematically written as 
, Equation 11 
where Vin and Vex are the inhale and exhale volumes and HUin and HUex are the 
inhale and exhale Hounsfield units of the individual lung voxels. The theory 
behind Equation 11 stems from the assumption that CT voxel content is composed 
of a linear combination of water-like material with a CT value of 0 and air-like 
material with a CT value of -1000 (75). Explicit derivation of Equation 11 is 
provided by Castillo et al. (73). The left side of the equation represents the local 
physiologic specific ventilation and the resulting 3D image displays the 
ventilation throughout the lung (Figure 13)… 
 
Figure 12: An example of a vector map showing the deformation field. The deformation 
field links lung voxels together from the inhale phase to the exhale phase of the 4DCT 
dataset. 
51 
 
 
There were several steps taken to address the uncertainties in the 
ventilation image calculation process. We used 9x9x9 mm voxel averaging to 
account for noise in the CT image as well as any spatial errors in the deformable 
image registration algorithm. We visually inspected each ventilation image to 
check for image artifacts. Whenever relevant, we would re-segment the lungs in 
an attempt to mitigate the image artifacts. Furthermore, we manually checked 
each deformation map for any errors and discontinuities and if it would have been 
necessary we were prepared to rerun the deformation algorithm with different 
inputs in an attempt to gain a more spatially accurate deformation map. In 
additional, the ventilation images were assessed for self consistency (73). To 
assess for self consistency we compared the measured differences in lung volume 
with the ventilation-calculated differences in lung volume. The measured 
differences in lung volume were determined by taking the difference between lung 
volume of corresponding inhale and exhale image pairs. The calculated lung 
Figure 13: An example of a ventilation image overlaid on a coronal CT slice. 
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volume difference was determined by summing the voxel ventilation for the 
segmented lung.” 
It should be noted that other groups have proposed a different method of producing 
ventilation maps from 4DCT data. These methods calculate the Jacobian of the 
deformation field (68, 72) to produce ventilation maps. Castillo et al (73) have noted the 
similarities and differences between the density based method and the Jacobian based 
method of calculating ventilation images. Their main findings is that the Jacobian based 
method calculates a change in voxel volume while the density change based method 
calculates the change in air concentration in a particular voxel. 
There is potential for this new and exciting way of calculating ventilation to be 
incorporated into radiation pneumonitis dose response modeling. Therefore the purpose 
of this study was to incorporate ventilation based functional information into the 
modeling of radiation pneumonitis. Our hypothesis was that the accuracy of radiation 
pneumonitis dose response models can be significantly improved by incorporating 
ventilation based functional information. 
 The study will be divided into 2 portions. The first portion will use weekly 
calculated ventilation images to investigate the mid-treatment changes in lung function 
that occur throughout the course of radiation therapy. It should be noted that this is 
strictly not a modeling study but rather an exploratory investigation to assess ventilation 
change throughout the course of radiation therapy. Specifically, we wanted to quantify 
the ventilation change as a function of dose and as a function of anatomy. The second part 
of the study will aim to explicitly incorporate pre-treatment ventilation imaging into the 
modeling of radiation pneumonitis. 
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Serial Ventilation Study 
Methods 
The serial ventilation study is presented from the manuscript published by Vinogradskiy 
et al (64). 
“ Patient selection 
All the patients for this study were chosen from a previous protocol that 
was approved by our Institution’s Review Board. Under the protocol, patients 
underwent weekly 4DCT scans for the duration of their therapy (76). The protocol 
was designed to assess weekly lung volume change and weekly lung tumor 
motion. To be eligible for the study, patients had to have a pathological diagnosis 
of NSCLC, and their course of radiation therapy had to be scheduled for at least 4 
consecutive weeks. During the 4DCT scans, patients were immobilized using a 
VacLoc immobilization device (Med-Tech, Orange City, IA). The 4DCT images 
were acquired using cine mode on a multisclice helical CT scanner (Discovery 
PET/CT; GE Healthcare, Waukesha, WI). A physicist was present during each 
4DCT scan to make sure the patient’s breathing was not erratic; however, no 
attempt was made to make breathing equivalent from week to week. We chose 6 
patients for our study from this protocol. The patients were chosen retrospectively 
to represent a wide range of clinical scenarios. 
  The treatment characteristics of all 6 patients are listed in Table 10 and the 
patient and tumor characteristics are listed in Table 11. Two of the patients were 
treated with proton therapy, and 4 patients were treated with IMRT. Two patients 
experienced severe (grade 3-5) radiation pneumonitis, and 3 patients had prior 
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Table 10. Summary of treatment characteristics. 
 
 
 
 
 
 
Table 11. Summary of patient and tumor characteristics. 
 
 
 
 
 
 
lung diseases (such as emphysema and COPD). Each patient had either 7 or 8 
4DCT datasets, the first of which was acquired prior to the beginning of 
treatment.” 
 
 
Patient 
Treatment 
Modality 
Prescription 
Mean Lung 
Dose (Gy) 
Presence of severe 
pneumonitis (time 
to toxicity) 
1 Proton 35 x 2.5 Gy 12.14 Yes (148 days) 
2 IMRT 35 x 2 Gy 16.81 no 
3 Proton 37 x 2 Gy 14.05 no 
4 Proton 37 x 2 Gy 19.27 no 
5 Proton 37 x 2 Gy 19.63 Yes (246 days) 
6 IMRT 33 x 2 Gy 19.02 no 
 
 
Patient Age Gender 
Prior Lung 
Disease 
Tumor location 
Tumor 
Stage 
Tumor Histology 
1 73 M 
COPD, 
Emphysema 
Left lower lobe IB 
Non-differentiated  
NSCLC 
2 67 M none Right upper lobe IIIB 
Non-differentiated 
 NSCLC 
3 68 M none Left upper lobe IIIB Squamous cell 
4 71 F none Left lower lobe IIIA Squamous cell 
5 77 F COPD Left upper lobe IIIB Squamous cell 
6 72 M Emphysema Right lower lobe IIIA Squamous cell 
 
 
The ventilation images were calculated (using the methods previously described) for each 
week for every patient. The ventilation image processing was done in the manner 
described by Vinogradskiy et al (64). 
“Ventilation image processing 
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Once all the ventilation images were calculated, the next step was to 
normalize the data. We normalized the data by converting ventilation images to 
percentile images (59, 65, 73). Converting ventilation maps to percentile images 
as a normalization method was advantageous because it was the method least 
sensitive to the maximum ventilation value on a particular image. In other words, 
an erroneous hot spot minimally affected the scaling of the rest of the image. The 
percentile was determined by ordering the ventilation values and for each value 
calculating the percent that fell below that certain value. 
To perform a quantitative analysis, it was necessary to have all the weekly 
ventilation images defined on the same coordinate system. Because the ventilation 
image is defined on the exhale CT coordinate system, we could register the exhale 
CT data sets and then apply the same transformations to the ventilation images. 
For each patient, we registered the exhale CT data set of each week to week 0 
(which we define as the pre-treatment CT data set) using deformable image 
registration (77). All registrations were visually inspected by overlaying each 
week’s exhale CT data set with the week 0 data set for that particular patient. 
Once the CT data were registered, the deformable transformations were applied to 
the ventilation maps.   
Having all the ventilation images defined on the same coordinate space 
enabled us to perform a quantitative analysis. We performed a quantitative 
analysis by defining ROIs and tracking the ventilation values of those ROIs 
throughout each week of therapy. We defined ROIs in two ways: according to 
dose and according to anatomy. For the dose ROIs, we defined the ROI as the 
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volume that received greater than or equal to 20 Gy (V20). The V20 was chosen 
because it is a common metric used in thoracic treatment planning and evaluation. 
We defined the anatomical ROIs by contouring the lobes of both the left and right 
lungs. Once the dose and lobe ROIs were defined we calculated the average 
percent ventilation for each ROI. The lung mask described was applied to the 
ventilation images at every time point. Therefore, the tumor volume was masked 
out for each weekly ventilation image. It should be noted that one patient had a 
tumor volume that occupied the entire lung lobe during pre-treatment. Therefore, 
for that particular patient we excluded the week 0 data point. In summary, our 
data included percent ventilation values for each patient, each week, and each 
lung lobe as well as percent ventilation values for each patient, each week and 
each V20 region. 
To study ventilation change throughout treatment, we made a plot of the 
average percent ventilation for each ROI as a function of treatment week and 
performed a linear fit to the data (Figure 14). The slope of the linear fit was the 
metric used to evaluate ventilation change throughout treatment. A positive slope 
indicated an increase in ventilation in a particular ROI throughout treatment; a 
slope of 0 indicated no change in ventilation; and a negative slope indicated a 
decrease in  
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ventilation. As an example, Fig. XX shows a lobe that had an increase in 
ventilation throughout treatment and a lobe that had little to no change in 
ventilation. 
Analysis of ROI data 
 The V20 ROI ventilation and slope data were used to study how ventilation 
changed throughout treatment as a function of dose. Specifically, we calculated 
the change in percent ventilation for the V20 ROI from pretreatment (week 0) to 
the final week of treatment. To evaluate the general trend in ventilation change 
with dose, we used the slope of the linear fit to the V20 ROI data. 
 In addition to dose, the ventilation in the different lobes of the lung was 
evaluated. Anatomically, ventilation is affected by airway opening or constriction, 
Figure 14: An example of ventilation data and the linear fit for 2 different lobes. The slope 
of the fit to the lobe 2 data was 3.43, while the slope of the fit to the lobe 1 data was 0.2, 
which indicated that lobe 2 showed an increase in ventilation over the course of treatment 
and lobe 1 had little to no change in ventilation over the course of treatment. 
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and the best way to investigate this physiologic phenomenon using the available 
data is to organize the data according to lung lobe. First, we evaluated only the 
pretreatment (week 0) ventilation data. We grouped all the lobes into 2 categories, 
lobes that contained the GTV and lobes that did not contain GTV, and evaluated 
the average ventilation for each group. We categorized the lung lobes in this 
manner because we hypothesized that lobes that contained GTV were more likely 
to experience airway constriction and ventilation would therefore be significantly 
lower for those lobes.  
Next, the lobe data were evaluated for all the treatment weeks. 
Particularly, we studied the slope of the linear fit to the lobe ROI data. We 
grouped all the lobes into 2 categories: lobes that contained GTV volumes that 
shrank and lobes that either did not contain the GTV or where the GTV did not 
get smaller. The slopes of the linear fit were statistically compared between the 2 
groups of lung lobes using a t-test. Our hypothesis was that throughout treatment, 
the tumor was likely to decrease in volume and cause airway opening for a 
particular lobe and therefore one would expect the ventilation to increase 
throughout treatment for that particular lobe.  
Results 
Ventilation as a function of dose  
The ventilation data for the V20 ROIs are displayed in Table 12. 
Ventilation increased in 4 patients and decreased in 2 patients between the final 
week of radiation therapy and week 0 (defined as pre-treatment). Four patients 
had a positive slope (slopes of 1.1, 1.4, 1.5, 0.3) of the linear fit to the ventilation 
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Table 12. Percent ventilation data for ROIs defined according to V20. 
 
 
 
 
 
 
 
versus week data, indicating an increase in ventilation for the V20 region over the 
course of treatment. Two patients had a negative slope (-0.6, -0.5), indicating 
decreased ventilation. We found no consistent relationship between dose and 
ventilation; ventilation increased in some patients over the course of treatment and 
slightly decreased or did not change in others. 
Patient 
Week 0 Percent 
Ventilation for 
V20 ROI (%) 
Final Week of 
therapy Percent 
Ventilation for V20 
ROI (%) 
Difference in Percent 
ventilation between 
the final week and 
week 0 (%) 
Slope of linear fit 
to Ventilation data 
(%/Week) 
1 56.5 54.1 -2.5 0.3 
2 30.1 35.8 5.7 1.1 
3 46.9 51.4 4.5 1.4 
4 34.7 43.4 8.6 1.5 
5 56.8 58.6 1.8 -0.6 
6 54.1 53.2 -0.9 -0.5 
 
 
Pretreatment ventilation by lobe 
 Visually, pretreatment ventilation appeared to be lower in lobes that 
contained tumor. The decrease in ventilation was particularly evident when the 
tumor was occluding a central bronchial airway; a representative case is shown in 
Figure 15. To quantify this phenomenon, the lobes were categorized into 2 
groups: lobes that contained tumor and lobes that did not contain tumor. The 
average pretreatment percent ventilation was 39±14% (mean ± standard deviation) 
for lobes that contained tumor and 54±15% for the lobes that did not contain 
tumor (Figure 16). The difference in ventilation between the 2 groups was 
statistically significant (p=0.017 using a t-test). 
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Figure 16: Comparison of ventilation between lobes that contained tumors and lobes that 
did not contain tumors. The difference in average percent ventilation was shown to be 
statistically significant (p=0.017 using a t-test). 
Figure 15: The dose distribution (A) and percent ventilation maps (B) for patient 2. The 
data for this patient provides a representative example of decreased ventilation for the left 
upper lobe where the tumor caused a central bronchial occlusion. 
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Change in ventilation by lobe over the course of treatment 
Two distinct patterns emerged when we qualitatively analyzed the series 
of weekly ventilation images for each patient. When tumor volume was visibly 
reduced, ventilation appeared to increase in the lobe where the tumor volume was 
reduced. A representative case is shown in Figure 17. When tumor volume was 
not visibly reduced, the 3D ventilation distribution did not change throughout 
treatment. A representative case is shown in Figure 18. To assess both trends 
quantitatively, we grouped the lobes into 2 categories: lobes that contained GTV 
volumes that shrank and lobes that either did not contain the GTV or where the 
GTV did not get smaller. The GTV volume reduction for each patient is shown in 
Table 13. Except for patient 3, all patients experienced a decrease in GTV volume 
from pre-treatment to the final week of treatment. Therefore, we grouped lobes 
that contained tumor for patients 1,2,4,5,6 into one group and lobes that did not 
contain GTV for patients  
62 
 
 
 
Figure 18: Tumor outline and dose distribution (A) as well as the weekly progression of 
ventilation images (B) for patient 3. This patient provides a representative example of a 
case where there was no visual evidence of the tumor volume reduction and as a result the 
ventilation distribution remained unchanged throughout treatment. 
 
Figure 17: Tumor outline and dose distribution (A) as well as the weekly progression of 
ventilation images (B) for patient 4. This patient provides a representative example of 
increasing ventilation in the left upper lobe as the tumor decreases in size. 
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Table 13. GTV volume for each patient recorded during pre-treatment and during the 
final week of therapy. 
 
 
 
 
 
 
 
Patient 
Week 0 Volume 
(cc) 
Final Week Volume 
(cc) 
Percent difference 
(%) 
1 339.6 148.7 -56.2 
2 37.5 21.5 -42.5 
3 45.3 45.3 0.1 
4 178.8 93.8 -47.6 
5 266.1 63.3 -76.2 
6 100.6 72.1 -28.3 
 
1,2,4,5,6 and all lobes for patient 3 into another group. The slope of the linear fit 
to the weekly ventilation data was assessed for both groups. The average slope 
was 1.18±1.49 for the group that contained tumors that shrank and -0.32± 1.37 for 
the group that did not contain tumor (or contained tumors that did not get 
smaller). The results were statistically different between the 2 groups (p=0.014 
using a t-test). A slope of 1.18 indicates that ventilation increased throughout 
treatment, while a slope of -0.32 is taken to mean little to no change in ventilation 
throughout treatment. The quantitative results confirm the visual observation that 
ventilation increased as the tumor shrank and remained unchanged when there 
was no change in the tumor and the surrounding thoracic anatomy. 
Discussion 
The ventilation results obtained using the dose (V20) ROIs suggest that 
there is no clear relationship between dose and ventilation function. For some 
patients, ventilation increased as a function of dose, and for others, ventilation 
remained unchanged or slightly decreased as a function of dose. These results are 
in line with the mixed data reported by Ding et al. (72), who found decreasing 
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ventilation for lung regions receiving greater than 24 Gy, and decreasing and 
increasing ventilation for lung regions receiving less than 24 Gy. It should be 
noted that our methods of calculating ventilation were slightly different than those 
used by Ding et al. (68, 72).  Furthermore, another difference between the studies 
is that the post radiation therapy 4DCT images from the Ding et al.
 
(72) study 
were not acquired during the last week of radiation therapy, as was done for our 
study. The biggest factor impacting ventilation is airway obstruction, and in the 
case of lung cancer, airway obstruction is most influenced by anatomical changes 
to the tumor. In our study, we believe that the lack of a clear relationship between 
dose and ventilation was related to the lack of a consistent relationship between 
dose and changes to the tumor. In some cases, radiation dose caused the tumor to 
shrink significantly, which led to airway opening and an increase in ventilation; 
while in other cases, radiation dose had little impact on the tumor size and the 
surrounding anatomy, causing either a slight decrease or no change in ventilation. 
Whether or not radiation alone (with no accompanying changes to the tumor) 
causes a decrease in ventilation is a topic of ongoing research. The dose and lobe 
results for the 6 patients in our study indicate that when there is no change in the 
thoracic anatomy, radiation damage to the lung alone does not cause a 
measureable decrease in ventilation. However, it is possible that the re-ventilation 
due to airway opening masks the effect of ventilation decrease due to radiation 
induced lung damage.  Furthermore, it is possible that the uncertainties involved 
in the ventilation image calculation process also mask the dose effects. 
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When looking at the pretreatment ventilation data, both the representative 
case (Figure 15) and quantitative (Figure 16) results suggest that lobes that 
contained tumors had a lower ventilation value and were therefore less functional. 
This result can be explained physiologically by the fact that the tumor caused a 
bronchial airway occlusion and the lobe was consequently less ventilated (Figure 
15). The airway occlusion appears clearly on the ventilation map but is not as 
obvious on a conventional CT scan. Since 4DCT scans are acquired as part of 
routine clinical care, the extra lung function information comes at no extra 
dosimetric or monetary cost to the patient. A ventilation image that shows obvious 
ventilation defects (Figure 15) could potentially be used to optimize treatment 
plan design, as described by Yaremko et al. (59). However, further work is needed 
to verify the ability of 4DCT-based ventilation imaging to identify ventilation 
defects due to airway occlusion caused by tumors. In the current work, data for 6 
patients was analyzed; an ideal study would include more patients and compare 
defects measured using 4DCT-based ventilation against defects measured using 
SPECT-based ventilation imaging. Preliminary work by Castillo et al. (59, 73) 
suggests that the highest correlation between 4DCT-based ventilation and 
SPECT-based ventilation occurs for the lowest percent ventilation values 
(ventilation defects). 
The qualitative (Figure 17 and Figure 18) and quantitative weekly results 
suggest that 2 distinct phenomena occurred. When tumor volume was reduced and 
an airway was opened, spatial ventilation was likely to increase; when there was 
no change in tumor or thoracic anatomy, ventilation was likely to remain the same 
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or decrease slightly. Ding et al. (72)
 
performed a similar analysis looking at the 
ventilation change for ipsilateral and contralateral lung. They reported a larger 
increase in ventilation in the ispsilateral lung than the contralateral lung. 
Seppenwoolde et al. (43) also noted re-ventilation (and reperfusion) as a function 
of the changing tumor anatomy. Our results and those reported by Ding et al. (72) 
and Seppenwoolde et al. (43) can be explained by the physiology of ventilation. A 
ventilation defect is likely to occur if an airway is blocked, and ventilation is 
likely to improve if the tumor decreases in size and an airway is opened.   
We chose to normalize the ventilation images by converting them to 
percentile maps based on methodology previously used in the literature
 
(59, 65, 
73)
 
There are other normalization methods that can be used. For example, the 
ventilation image could be normalized by dividing by the maximum pixel value in 
a particular image or by normalizing images for all weeks by a pre-determined 
ventilation maximum. Seppenwoolde et al.
 
(43) normalized SPECT based 
perfusion images used for a longitudinal study on low dose (< 8Gy) and highly 
perfused regions of the lung. In the case of weekly 4DCT-based ventilation 
images we believe converting to a percentile image is ideal because it is the 
method least sensitive to the maximum ventilation value on any particular image 
and because each week’s ventilation image is normalized to itself. Normalizing 
each week’s ventilation image to itself is advantageous because patients may be 
breathing with different amplitudes during each treatment week. 
There were several limitations to our study. Although much progress has 
been reported on 4DCT-based ventilation imaging (59, 65, 68-71), the methods 
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for calculating ventilation are still being perfected. For example, 4DCT-based 
ventilation calculations are sensitive to image registration spatial errors, and 
several groups are working on methods to mitigate the effect of the registration 
uncertainties (72, 74). In addition, the reproducibility of 4DCT-based ventilation 
imaging has yet to be investigated. The reproducibility of 4DCT-based ventilation 
imaging is highly dependent on the reproducibility of the 4DCT captured 
breathing cycle. We hypothesize that global defects investigated in this study 
would appear consistently in the same region regardless of the captured breathing 
cycle; however, future work is needed to investigate the reproducibility of 4DCT-
based ventilation maps. The process of calculating ventilation images from 4DCT 
data is still being refined and is not yet fully automated; thus, user input is 
required throughout the calculation process. In our study, we registered weekly 
ventilation images by registering the corresponding exhale CT datasets. For 
patients that showed a reduction in the GTV throughout treatment, the deformable 
image registration algorithm enlarged the weekly tumor volume in an attempt to 
match the image to the original pre-treatment tumor volume. The week to week 
image registration spatial errors may not impact the global ventilation 
characteristics investigated in our study; however, future work that attempts to 
perform a pixel by pixel analysis should consider the week to week spatial image 
registration errors due to tumor volume reduction.  Our data set consisted of 
images taken throughout the course of radiation therapy. However, radiation 
effects (to normal tissue and tumor) can occur weeks or months after radiation 
therapy. In future work, we plan to perform a similar analysis on data that 
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includes 4DCT images acquired several months after the completion of radiation 
therapy. Finally, in order to completely evaluate lung function it would be 
preferable to have ventilation as well as perfusion information.  
Conclusions 
In the current study we present a unique dataset of 4DCT-based ventilation 
images calculated weekly for 6 lung cancer patients undergoing radiation therapy. 
For our patient cohort, we did not find a consistent pattern of ventilation change as 
a function of radiation dose. Furthermore, we determined that pretreatment 
ventilation was significantly lower for lobes that contained tumors, particularly in 
cases where the tumor was occluding a central airway. The weekly lobe 
ventilation data indicated that when tumor volume is reduced the ventilation will 
increase and when there is no change in the thoracic anatomy, we did not measure 
a ventilation change.  Further developments mitigating the uncertainties and 
improving the robustness of the calculation method along with more data points 
will enable us to make stronger and more local conclusions about changes in 
ventilation for patients undergoing radiation therapy.” 
Pre-treatment ventilation study 
Methods 
 The purpose of this study was to incorporate ventilation-based functional 
information into the modeling of radiation pneumonitis and determine whether 
incorporating the functional information could improve the fit of our model. Initially, 120 
patients from the MD Anderson NSCLC patient database (described in the Patient 
Database section) were selected for this study. These were the patients that contained 
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data from 4DCT simulation. Upon reviewing the 4DCT images, we decided to exclude 45 
patients because of the poor quality of the 4DCT images. The poor quality was due to 
motion artifacts or because images did not encompass the entire volume of the lung. As a 
result, we had 4DCT data for 75 patients from our 1999-2005 patient database. In order to 
increase the number of patients in our study, we selectively chose 17 patients from a 
database that was being accumulated for 2006. This NSCLC database contained similar 
information to the 1999-2005 database but contained patients that were treated in 2006 
(rather than 1999-2005). We selectively chose patients to include a majority of patients 
that went on to develop severe (grade 3-5) radiation pneumonitis. The rationale and 
limitations of selectively choosing patients will be addressed in the discussion section.  
 For each patient we used the pre-treatment 4DCT data to calculate a pre-treatment 
ventilation image using the methodology previously described. We normalized the data 
by converting each ventilation image to a percentile image. Each patient’s treatment plan 
was restored into the treatment planning system providing information about the dose 
distribution. By definition, the ventilation image is defined on the same coordinate system 
as the exhale phase (50%) of the 4DCT dataset. The exhale CT phase is defined on the 
same CT coordinate system as the CT data set (average CT dataset) used to calculate 
dose. Therefore, the ventilation image and the dose distribution were inherently 
registered. 
 For each patient we calculated a DVH and a dose-function histogram (DFH). The 
DFH was calculated in the manner proposed by Marks et al (61). The first step in 
computing the DFH was to group the data into dose bins and for each bin add the 
normalized ventilation values corresponding to that dose bin. The bins were normalized 
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by dividing each bin by the sum of all bins in the histogram. A cumulative DFH was then 
calculated by summing the fractional ventilation of all the dose bins greater than or equal 
to the dose of each bin. In addition we calculated a MLD and a functionally weighted 
mean lung dose (fMLD). The fMLD was calculated by multiplying each dose voxel by 
the ventilation value of that voxel. Furthermore, we calculated an effective dose (Deff) and 
the functional effective dose (fDeff ) using Equation 3 with the n parameter set equal to 
0.5. Although it has been established that the volume parameter (n) is not different from 1 
for the lung (6) we decided to investigate different values for n because there has been no 
precedent set when investigating dose and ventilation relationships in the lung.  
 We grouped the data into 2 categories: patients who experienced severe (grade 3-
5) radiation pneumonitis and patients who did not experience severe pneumonitis (grade 
0-2). We compared the MLD, fMLD, Deff, and fDeff, values between the 2 groups using a 
two-sample ttest and a ranksum test (29). Furthermore, we incorporated the ventilation-
based functional information into a predictive risk model. We incorporated the 
ventilation-based functional information into the model described by Equation 10. The 
model described in Equation 10 is the same model that was used for the spatial study, 
except in this instance the weighting values (wi) were defined by the ventilation image. In 
other words, the weighting will not be defined by a spatial weighting scheme but rather 
by a ventilation weighting scheme. Similar to the methodology used for Specific Aim 1, 
we used the likelihood ratio test to compare the fit of the model that incorporates dose-
volume to the fit of the model that incorporates dose-volume and ventilation-based 
functional information. The likelihood ratio test will determine whether adding in an 
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additional parameter (ventilation-based functional information) can significantly improve 
the model fit to the data. 
Results 
 Individual patient examples of a dose distribution, ventilation map, DVH, and 
DFH are shown in Figure 19 and Figure 20. The example patient shown in Figure 19 had 
a mean lung dose of 22.9 Gy and did not develop severe radiation pneumonitis. The dose 
distribution and  
 
Figure 19: Dose distribution (A), ventilation image (B), and DVH and DFH example for 
one patient. This patient provides an example where dose was delivered to the non-
functional portions of the lung and where the DFH is lower than the DVH. This patient did 
not develop severe radiation pneumonitis 
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ventilation image (Figure 19) illustrate that this patient received the majority of dose to 
the non-functional and non-ventilation portions of the lung. As a result, the DFH appears 
well below the DVH. By contrast, the example patient shown in Figure 20 received a 
MLD of 23.2 Gy and did go on to develop severe radiation pneumonitis. The dose 
distribution and ventilation image indicate that the patient received dose to highly 
ventilated portions of the lung. As a result, the DFH appears greater than the DVH. 
Although the MLD and the DVHs of these patients are similar, the difference between the 
spatial dose and function combination of the 2 patients is highlighted using the DFH. 
 A scatter plot showing the fMLD versus the MLD is shown in Figure 21. This  
Figure 20: Dose distribution (A), ventilation image (B), and DVH and DFH example for 
one patient. This patient provides an example where dose was delivered to the functional 
portions of the lung and where the DFH is greater than the DVH. This patient went on to 
develop severe radiation pneumonitis. 
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graph highlights the change of variable in going from the MLD to the fMLD. It is 
important to note that the scatter plot appears spread out and the data does not lie on a 
straight line. If the data were to lie on a straight line that would indicate that weighting 
the dose with the ventilation values would not add any extra information in addition to 
the  MLD. Furthermore, a linear fit to the data is shown in Figure 21. The pneumonitis 
rate above the line is 22.4% and 12.8% below the line. This indicates that the fMLD helps 
separate the toxicity data better than the MLD. 
 The box plot (Figure 22) shows that the fMLD was higher for patients that 
developed severe radiation pneumonitis. However using a two-sided ttest the difference 
between the 2 groups was not significant (p = 0.251). Furthermore, there was no 
difference between the 2 groups in the MLD, Deff (using n = 0.5), and fDeff (using n = 0.5), 
Figure 21: Scatter plot showing the variable change from MLD to ventilation weighted 
MLD (fMLD). A linear fit to the data is shown as a black line. The pneumonitis rate is 
22.4% above the line and 12.8% below the line. 
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Table 14. Significance values for the various dose-volume and ventilation weighted 
dose-volume metrics that were investigated. The significance values indicate a 
difference in the metric between the group that developed severe pneumonitis and the 
group that did not develop severe pneumonitis.  
 
 
 
 
using either a ttest or a ranksum test (Table 14). When the model parameters were 
determined for the dose-volume model (Equation 4) the m and TD50, values were 
calculated to be 0.76 and 70.66 respectively. The parameters for the dose-volume and 
functional model (Equation 10) were calculated to be 1.38 x 10
6
, 0.61, and  
 
Dose-volume 
metric 
ttest ranksum test 
MLD 0.585 1 
fMLD  0.251 0.372 
Deff (n=0.5) 0.350 0.788 
fDeff (n=0.5) 0.118 0.238 
 
Figure 22: Box plot comparing the ventilation weighted MLD between the pneumonitis 
and non pneumonitis group. As expected the group that developed pneumonitis had 
higher ventilation weighted doses than the group that did not develop pneumonitis. 
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6.04 x 10
4
, for the m, TD50, and C values respectively. Using the likelihood ratio test the 
difference in fits of the two models was not found to be significant (p = 0.312).  
Discussion 
 We have combined some novel techniques along with the methods proposed by 
Nioutsikou et al (42) and Miften et al (41)  to incorporate ventilation-based functional 
information into the modeling of radiation pneumonitis. The individual patient examples 
(Figure 19 and Figure 20), scatter plot (Figure 21), and box plot results are promising. 
The patient examples illustrate how the combination of dose and function information can 
lead to a better understanding of the effect of radiation on the normal lung. The scatter 
plot shows that converting from MLD to a fMLD will separate the data, meaning that the 
two metrics are not equivalent. Furthermore, using a linear fit, the scatter plot 
demonstrated graphically that the fMLD is a better predictor of pneumonitis than the 
MLD. As expected, the box plot indicates that the fMLD is greater for patients that 
developed severe radiation pneumonitis than for patients that did not develop severe 
radiation pneumonitis. However, using statistical analysis and maximum likelihood 
methods the results were not shown to be significant. Based on the promising initial 
results we believe the statistical results can be improved by incorporating more patients in 
future work. 
 The current study contained 96 patients; while this is consistent with the number 
of patients in similar studies (43, 78, 79), an important question to address is how many 
patients would be needed to find a statistically significant result. In order to determine 
how many patients would be needed we performed a sample size simulation. The idea of 
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the simulation was to simulate data based on existing results, perform the statistical test 
we were interested in and calculate how many samples are needed for a power ratio of 
80%. The power ratio is defined by the ratio of the number of successful samples to the 
total number of samples. Successful samples could imply statistical significant results at 
the p = 0.05 level or cases where a certain p value is larger than another p value. The first 
step was to simulate the pneumonitis data. Out of the entire patient population we decided 
to simulate a 50% pneumonitis rate. While 50% is not representative of a true 
pneumonitis rate, an assumption is made that we are able to selectively pick our data. 
Then for the pneumonitis and non-pneumonitis groups we simulated MLD and fMLD. 
The MLD and fMLD were generated for the pneumonitis and non-pneumonitis group 
using a normal distribution and mean and standard deviation values calculated from our 
existing data. For example, the simulation of the MLD was simulated with a mean of 
20.58 and a standard deviation of 4.55 (Figure 23).  Once all of the MLD and fMLD 
values were simulated we performed a ttest comparing the MLD amongst the 
pneumonitis and non pneumonitis group and a ttest comparing the fMLD among the 
pneumonitis and non pneumonitis group. We calculated the power as the number of times 
the p value for the fMLD ttest was smaller than the p value for the MLD ttest normalized 
by the total number of simulation. In order to reach 80% power, 680 simulations were 
needed. It is also possible to perform a power calculation using regression analysis with a 
probit link. When we performed a regression analysis with the MLD and fMLD, 610 
simulations were needed for a power of 80%. It should be noted that the regression 
analysis is not the ideal test to use because the pneumonitis events are being artificially 
selected. However, it is promising that both statistics needed around 650 patients for a 
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power ratio of 80%. Although there are assumptions made in the simulation that could 
affect the sample size calculation, the exercise underlines that a much larger sample size 
would be needed to prove statistical significance. 
 
 Because 4DCT-based ventilation imaging is a new method of calculating lung 
function, most of the literature has focused on the methodology to calculate ventilation 
and as a result there are no papers relating ventilation-based functional information to 
radiation pneumonitis. Yaremko et al (59) demonstrate that it is possible to reduce highly 
ventilated portions of the lung using IMRT; however, this is mostly a methodology paper 
and does not relate ventilation to clinical symptoms. Because of readily available data, 
Figure 23: A histogram of the simulation results for the entire population MLD. The 
histogram confirms that the simulation mean and standard deviation of the normal 
distribution were 20.58 and 4.55 resepctively. 
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most of the literature has focused on incorporating SPECT-based perfusion imaging into 
the prediction of thoracic radiation toxicity. Several studies have tried to correlate 
SPECT-based perfusion changes with pulmonary function test (PFT) data. Studies by Fan 
et al (78) and Ma et al (63) found significant results in correlating perfusion changes with 
PFT changes; however, the studies noted modest correlation coefficients (0.18 – 0.30). 
Lind et al (79) incorporated dosimetric and perfusion information and used receiver 
operating characteristic (ROC) analysis to evaluate the predictive abilities of each metric. 
They report that the models that incorporated dose and perfusion were best correlated 
with pneumonitis; however, they report an area under the ROC curve in the range of 0.61-
0.72. These values are not an indicator of a strong relationship between dose and 
perfusion with radiation pneumonitis. Seppenwoolde et al (43) report that the overall 
mean perfusion-weighted lung dose and mean perfusion-weighted  regional doses to the 
posterior, inferior, ipsilateral, and central regions were associated with radiation 
pneumonitis. They also report that the doses to the entire lung and regional doses (not 
accounting for perfusion) were correlated with pneumonitis. In this instance, it is difficult 
to distinguish between correlations caused by dose and correlations caused by dose to 
functional portions of the lung. Kocak et al (40) developed a model to incorporate dose 
volume and perfusion into the prediction of pneumonitis and applied their model to an 
independent data set. They report that their model was not able to accurately segregate 
patients into high and low risk groups. Our data is in line with the results proposed in the 
literature. Both our results and those of others (40, 43, 63, 78, 79) provide some 
promising initial findings; however, the data does not turn out to be statistically 
significant in most cases. There are several possible explanations. One explanation for the 
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lack of statistical significance is the number of patients in the studies. Specifically, the 
number of patients developing radiation pneumonitis is low.  With more patients, the 
number of patients developing radiation pneumonitis would increase and the statistical 
metrics would improve. Our sample size simulation suggested that around 600 patients 
would be needed for significant results; however, most of the studies are limited to 
around 100 patients. Another possible explanation is the lack of biological understanding 
of the relationship between lung function and symptomatic toxicity. There are several 
metrics and imaging modalities that have been used to describe lung function. These 
include: PFT, perfusion, ventilation, diffusion, and inflammation. There is no clear 
conclusion in the literature that any of the metrics (or any combination of the metrics) can 
be used to completely describe lung function and lung damage. The current study and 
many of the studies in the literature investigate the relationship between one metric and 
symptomatic radiation pneumonitis. It is possible that a combination of the imaging 
modalities (for example ventilation, diffusion, and perfusion) is needed to completely 
describe lung function and to demonstrate the relationship between lung function and 
symptomatic toxicity. 
 There were several limitations to our study. As stated previously, we believe with 
more patients the statistics of our study could be improved. However, we do not believe 
the number of patients in this study was unreasonably low. We analyzed 96 patients for 
this study, by comparison Lind et al (79) had 166, Fan et al (80) had 96, and 
Seppenwoolde et al had (43) 106. In order to increase the number of pneumonitis events 
in our study we manually selected a portion of our data. Because some of the data were 
manually selected, the pneumonitis rate is not representative of the patient population at 
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MD Anderson and therefore the modeling parameters cannot be compared with those 
published in the literature. However, because the likelihood ratio test calculates an 
improvement in model fit to the data, the significance value stated is valid, despite the 
manually selected patient population. Furthermore, the ttest and ranksum statistics 
comparing the MLD and fMLD for the pneumonitis and non-pneumonitis group are valid 
as well, despite the manual selection of the data. All of the uncertainties associated with 
calculating ventilation images discussed in the Serial Ventilation study apply to this 
section as well. Particularly is worth noting that the ventilation images are sensitive to the 
particular breathing cycle captured by the 4DCT. We normalized our data by converting 
the ventilation images to percentile images. We normalized the data in this manner 
because this was the method previously used in the literature (59, 65, 73) and because it is 
the method that best mitigates the uncertainties associated with calculating 4DCT-based 
ventilation. However, there are other possibilities for normalizing the data. For example, 
it is possible to normalize the data using a universal maximum ventilation value or by 
using the maximum voxel value in a particular image. The magnitude of the ventilation 
images is dependent on the shallowness and depth of the breathing cycle captured by the 
4DCT. Certain patients may not take as large a breath and therefore their ventilation 
values would be smaller than those of patients who took a deeper breath. This would be 
equivalent to administering differing amounts of radionuclide in SPECT exam. Patients 
may have different magnitude values of their ventilation image that may not necessarily 
be associated with function but rather the amplitude of the breathing captured by 4DCT. 
As a result, we believe it is best to normalize the ventilation images to themselves (as 
opposed to using a population based normalization value). Furthermore, by using the 
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percentile image we mitigate the effect of the maximum voxel value on the rest of the 
image, which is important because the maximum voxel ventilation values are often the 
most prone to the uncertainties associated with calculating 4DCT images. In this study, 
we attempted to associate ventilation with lung function and symptomatic pulmonary 
toxicity. As mentioned previously, lung function can be defined by ventilation, perfusion, 
diffusion, inflammation, and PFT data. Therefore, in future work it would be informative 
to combine these modalities to better determine lung function and improve the prediction 
for radiation pneumonitis. In addition, as the patient database grows, it would be 
informative to correlate lung function (as measured by ventilation) by more specific 
patient groups according to: age, PFT data, and prior lung disease. 
Conclusions 
 In this study we used pre-treatment 4DCT-based ventilation images to determine 
lung function and help predict for radiation pneumonitis. The hypothesis of the study is 
rejected because we were not able to achieve a significant improvement in model fit by 
incorporating ventilation-based functional information. Although we were not able to 
achieve a significant improvement in model fit with our 96 patient database, we show 
some promising results indicating that ventilation imaging can provide useful information 
about lung function in lung cancer patients. We believe more patients are needed to 
demonstrate a significant relationship between dose to highly ventilated portions of the 
lung and symptomatic radiation pneumonitis.  
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Specific Aim 3 – Personalized prescription study 
Introduction 
Dose escalation trials have been performed that report promising results for lung 
cancer patients receiving radiation therapy. Dose escalation trials can broadly be 
categorized into 2 types of dose escalation schemes: randomized dose escalation and dose 
escalation using dose-volume metrics. The study by Perez et al (11) provides an example 
of a randomized dose escalation scheme where patients get randomized to a treatment 
arm and depending on the treatment arm they receive a certain amount of dose to the 
tumor. More recent studies have employed dose escalation schemes that are based on 
dose-volume metrics. For example, Bradley et al (16) escalated doses based on V20 while 
Belderbos et al (46) and Van Baardwijk et al (48) escalated dose based on MLD. The 
group at the University of Michigan went a step further and used NTCP models to 
calculate effective volume (Veff) and determine the dose based on Veff  (45). It should be 
noted that although the study explicitly incorporated NTCP modeling into the 
determination of dose, the NTCP model was based solely on dose-volume metrics. 
 In addition to dose volume, researchers have attempted to incorporate other 
patient and clinical factors as predictive factors for severe radiation pneumonitis. As 
noted earlier, studies have proposed a correlation between radiation pneumonitis and 
chemotherapy (35), performance status (36), smoking status (37), tumor location within 
the lung (32, 33, 39), and functional status of the lung (40-42). One of the factors that has 
been investigated in relationship to radiation pneumonitis has been genetic information in 
the form of SNPs (38). SNPs are a type of biomarker and are considered to be DNA 
sequence variations. Recent research interest has been focused on identifying SNPs 
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associated with different inflammatory cytokines (signaling proteins). Yuan et al (38) 
showed that the CT/CC genotypes of the cytokine transforming growth factor B1 
(TGFB1) gene were associated with a lower risk of radiation pneumonitis. In a similar 
study, Anscher et al (81) evaluated 73 patients that were treated with definitive 
radiotherapy and determined that TGFB1 appeared to be a useful means to identify 
patients at low risk for developing radiation pneumonitis. It should be noted however that 
the data is not consistent. For example, the results reported by De Jaeger et al (82) did not 
confirm that increased levels of TGFB1 were a risk factor for developing pneumonitis. 
Other SNPs have also been investigated. Fogarty et al (83) studied the SNP MC1R and 
found that it was associated with unexpectedly high severe acute reactions to radiation 
therapy. In a recent study (84), our group incorporated SNPs as biomarkers into a 
predictive LKB NTCP model. We analyzed 143 patients with NSCLC treated definitively 
with radiation therapy. The study genotyped 15 potentially functional SNPs and found 
that TGFB073 = TT, XRCC_NIH = WW, and VEGF4039 = CT/TT, were selected as 
adverse risk factors. In other words, patients with the above mentioned genotypes of the 3 
SNPs were at a greater risk for developing radiation pneumonitis.  
 The next logical step in dose escalation studies is to prescribe dose based on 
NTCP models. Specifically, using NTCP models that are further individualized because 
they incorporate additional factors bedsides dose-volume. By using NTCP models that 
account for patient and clinical factors, the derived lung dose limit and subsequent target 
dose prescription can become personalized to the patient, rather than being population 
based. The concept of personalizing a lung dose limit to individuals is an idea that certain 
thoracic physicians may do already. For example, when deciding how much dose can 
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safely be delivered to the lung, physicians may consider the patient’s chemotherapy 
status, surgery status, or PFT scores. However, as additional factors are found to be 
associated with radiation pneumonitis a more rigorous approach is needed. The concept 
of personalizing the lung dose limit and the prescription dose are demonstrated in the 
current study. We perform a virtual dose prescription trial where the prescription is 
determined using an individualized lung dose-volume constraint that is calculated using a 
NTCP model. We will use a model that is composed of dose-volume and genetic (SNP) 
information. Our hypothesis is that the median difference between the model-determined 
prescription and the clinically achieved prescription will be greater than a clinically 
significant threshold of 5 Gy.  
Methods 
 The patient database used for this study was taken from our previous work (84). 
The study published by Liao et al (84) contained 143 patients; however, we were only 
able to de-archive 141 patients into the treatment planning system. Therefore, 141 
patients were used for this simulation. The patients had a diagnosis of NSCLC and were 
treated with definitive radiation therapy both with and without concurrent chemotherapy. 
The distributions of genotypes for each SNP are shown in Figure 24. Each genotype was 
well represented within the patient population except for the TT genotype of the VEGF 
SNP (which was represented by 3 patients). 
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The first step was to mathematically describe the model that would be used to 
determine the personalized lung dose limit. To incorporate dose-volume and SNP 
information we used the LKB NTCP formulation described in Equations 1 and 7. The 
TD50 and m values that were fit to the data were determined to be 36.6 Gy and 0.381 
respectively. The SNP data were incorporated as DMF factors. The total DMF (DMFT) 
was defined as  
         Equation 12 
where DMFXRCC, DMFTGFB, and DMFVEGF where the DMFs for the individual SNPs. For 
patients that had a genotype of WW for the XRCC SNP the DMFXRCC = 0.681, for 
Figure 24: Distribution of genotypes for each 
SNP. The red bars represent genotypes that 
were selected as adverse risk factors for 
radiation pneumonitis and the blue bars 
represent genotypes that were not a risk 
factor for developing radiation pneumonitis. 
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patients that had a genotype of CT or TT for the VEGF SNP the DMFVEGF = 0.733, and 
for patients that had a TT genotype for the TGFB SNP the DMFTGFB = 0.783. If the 
patients did not have the genotypes described above for the 3 SNPs, then their DMFs 
were set to 1. These were all parameters that were fit to our patient database in the 
previous study (84). Each DMF factor can theoretically be thought of as effectively 
reducing the TD50 parameter in Equation 7. As the TD50 parameter gets reduced the dose 
response curve is shifted to the left, and for the same MLD there is a greater risk of 
pneumonitis, or conversely, a lower MLD is needed for the same risk of pneumonitis. 
Therefore, each selected genotype moves the curve to the left and can be theoretically 
thought of as increasing a patient’s risk for radiation pneumonitis. The NTCP curves 
described in Equations 1, 7 and 12 are displayed in Figure 25.  
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There were 8 total curves in the plot because there are 8 different possible combinations 
of DMFXRCC, DMFTGFB, and DMFVEGF, resulting in 8 different possibilities for the DMFT. 
Conceptually, we know the genotype for each patient for the 3 SNPs (XRCC, TGFB, and 
VEGF) and therefore can determine which one of the 8 curves shown in Figure 25 the 
patient falls on. The next piece of information needed for the personalized lung dose limit 
is the acceptable complication probability. In theory, this would be the clinically agreed 
upon radiation pneumonitis complication probability and would be determined based on a 
clinical decision balancing tumor control and normal tissue toxicity. For the current 
Figure 25: NTCP curves for different combination of genotypes for the 3 SNPs 
investigated (XRCC, TGFB, VEGF). Knowing each patient’s genotype allows for each 
patient to be placed on one of the curves shown.. 
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study, we simulated several different scenarios. We simulated a pneumonitis rate of 22.6 
% because that was the true complication rate in our dataset. We also simulated 
complication probabilities of 20% and 25% to study the dependence of the prescription 
change on the complication probability. Once we know which curve each patient falls on 
and have an agreed upon complication probability we can determine a personalized dose 
limit for each patient (Figure 26).   
 
For example, for a complication probability of 22.6% it is possible to have a patient with 
a SNP genotype that calls for a MLD limit of 10 Gy, 15 Gy, or as much as 26 Gy (Figure 
Figure 26: Three example NTCP plots relating MLD and radiation pneumonitis 
complication probability. The plot illustrates that for 3 different patients with 3 different 
genotypes, using a complication probability of 22.6, the MLD limits would be personalized 
and different for each patient. 
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Table 15. Dose-volume limits used for the virtual simulation study. 
 
 
 
 
 
 
 
 
26). The MLD limit is “personalized” because it is based on each individual patient’s 
genotypical expression of the 3 SNPs. In the current approach, each patient has their own 
MLD limit (although in this study 8 different MLD limits exist), as opposed to a universal 
MLD limit that is applied to the entire patient population. In addition to the model 
derived lung dose limit, we applied treatment planning parameters to the spinal cord, 
esophagus, and the heart (Table 15). For the spinal cord we used a maximum dose  
Organ Limit 
Lung Model 
determined 
Spinal 
Cord 
Dmax < 50 Gy 
Esophagus V60 < 50% 
Heart V50 < 50% 
of 50 Gy, for the esophagus we used a V60 of 50%, and for the heart we used a V50 of 
50%. These are in line with the treatment planning parameters used in our clinic.  
 The DVH and dose-volume parameters for each patient’s clinically used plan 
were exported. It is important to note that at this point of the study, only the patient’s 
clinical plan was used. There was no re-planning or re-contouring, and we used the same 
beam arrangement and design as was used for the clinically delivered plan. We applied 
the model-determined MLD limit as well as the other treatment planning parameters to 
the dose-volume parameters exported from the patient’s clinical plan and determined if 
we could escalate the dose or if the dose needed to be lowered. If all of the clinical 
parameters fell below the model-determined MLD limit and the other organ limits, then 
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we could increase the prescription dose. Conversely, if some of the parameters exceeded 
the model-determined MLD limit or any of the other applied limits, then the prescription 
dose was lowered. The next step was to determine the quantity by which the dose needed 
to be escalated or de-escalated. To calculate the dose escalation or de-escalation, we 
calculated a ratio of the patient’s clinical parameters to the set treatment planning limits. 
It should be noted that while the MLD and the spinal cord max dose can be calculated as 
a linear scaling, in order to determine a ratio for the volume parameters (used for the 
esophagus and heart) the DVH needs to be used. For example, to calculate the possible 
dose escalation or de-escalation due to the esophagus, the ratio of 60 Gy to the D50 is 
taken. A graphical representation of how the ratio of doses was calculated using the DVH 
is shown in Figure 27.  
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Once all the ratios were calculated, for each individual patient, the organ with the 
minimum ratio was taken as the dose limiting organ. For example, if the dose could be 
escalated by 6% according to the lung limit and 15% according to the spinal cord limit, 
then the lung would be the dose-limiting organ and the dose could only be escalated by 
6%. Similarly for dose de-escalation, if the dose had to be lowered by -6% according to 
the lung limit and by -15% according to the spinal cord, then the spinal cord would be the 
dose limiting organ. Once the dose-limiting organ was determined, the dose escalation or 
Figure 27: An example of how an esophagus DVH is used to calculate the change in 
dose needed to change the V60 to 50%. First the D50 is identified, then the ratio of 60 Gy 
divided by D50 is taken as the amount the dose needs to be escalated (or de-escalated in 
some cases) to achieve a V60 of 50%. The theoretical movement of the DVH using a 
dose escalation ratio calculated by the method above is shown in green. For this patient 
example, the dose can be escalated by 600% based on the esophagus. In this patient 
example, the prescription dose would likely be limited by another normal tissue organ. 
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de-escalation scheme dictated by that organ was applied to the prescription dose as well 
as the other dose-volume parameters. We then noted the difference in the model-
determined prescription dose and the clinically used prescription dose. In other words, if 
the model-determined prescription was greater than the clinically achieved prescription, 
then according to the model we should dose escalate for that particular patient, if the 
model-determined prescription was lower than the clinically used prescription, then 
according to the model the dose needed to be reduced. In summary, we scaled the 
prescription dose for each patient according to normal tissue constraints. We used 
conventional dose-volume constraints for the spinal cord, esophagus, and heart, and a 
personalized MLD limit determined from a NTCP model. We studied the difference in 
the model-determined prescription dose and the clinically used prescription dose. The 
change in prescription was investigated as a function of the selected complication 
probability. We also noted the differences between the model-determined MLD limit and 
the clinically used MLD limit. Furthermore, in order to gain an understanding of the 
dose-limiting organ for the entire patient population, we noted the dose-limiting organ for 
each individual patient. For 31 of the patients in the study the clinically used dose-volume 
values for the spinal cord, esophagus, and heart, exceeded the dose-volume limits that we 
imposed for the study (prior to the model-determined MLD limit being applied). This 
occurred because the clinician made a decision to exceed dose-volume constraints in 
favor of better tumor control. To investigate the effect of having these patients in our 
study, we performed a simulation where the patients that had exceeded dose-volume 
constraints before the MLD limit was applied were excluded.  
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 It is instructive to go through the personalized dose prescription process for an 
individual patient example. The patient’s dose distribution is shown in Figure 28 and the 
dose-volume parameters, limits, and ratios are shown in Table 16.  
 
 
 
 
 
 
 
Figure 28: Dose distribution 
for the patient used in the 
example calculation. 
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Table 16: A single patient example of the procedure used to determine the model-
generated prescription. The table shows the patient’s clinical parameters, the 
applied dose volume limits, the ratio between the limits and the clinical 
parameters, and finally the model-generated parameters. 
 
 
 
 
 
 
 
 
 Prescription 
(Gy) 
MLD 
(Gy) 
Cord 
max (Gy) 
Esophagus 
V
60 
 (%)
 
 
Heart  
V
50 
(%) 
Clinical 60  23.6 43.2 37.5 26.1 
Limits  24.9 50 50 50 
Ratio  1.06 1.16 1.09 4.2 
Model- 
generated 
parameters 
63.6 24.9 45.8 49.7 23.5 
 
This particular patient received 3D-CRT with a prescription dose of 60 Gy. The MLD for 
the patient was 23.6 Gy, the esophagus V60 was 37.5%, and the heart V50 was 26.1%. The 
patient had a genotype of WP for the XRCC SNP, CT for the TGFB SNP, and CC for the 
VEGF SNP, corresponding to DMFs of DMFXRCC = 1, DMFTGFB = 1, and DMFVEGF = 
0.733, for a DMFT = 0.733. Using Equations 1 and 7, along with a DMFT = 0.733 and a 
complication probability of 20%, the personalized model-determined MLD limit for this 
patient is 24.9 Gy. The other limits are set as stated above; 50 Gy for the cord max dose, 
50% for the esophagus V60 and 50% for the heart V50. For this patient, all the dose-
volume parameters for the clinically used plan fell below the set limits; therefore, the 
dose could be escalated. Using a linear relationship, based on the MLD and spinal cord, 
the dose can be escalated by 6% and 16% respectively. Using the DVH, the dose can be 
escalated by 9% according to the esophagus and 320% using the heart. The minimum 
ratio for this patient is 6%; therefore the dose limiting organ will be the lung. The 6% 
dose escalation scheme is applied to the prescription dose as well as the other dose-
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volume parameters. The resulting prescription dose is 63.6 Gy, while the new MLD is 
24.9 Gy, the new spinal cord maximum dose is 45.8 Gy, the new esophagus V60 is 49.7% 
and the new heart V50 is 23.5%. The metric of interest for this study was the difference 
between the model generated prescription dose and the clinically achieved prescription 
dose, which for this patient is calculated to be +3.6 Gy. As expected, the MLD value is 
maximum, while the other dose-volume parameters don’t reach their maximum allowable 
values.  
Results 
 A histogram of the difference between the model generated MLD and the 
clinically achieved MLD for all patients is shown in Figure 29. Patients that fell to the left 
of zero are patients for whom the model predicted a lower dose than what was given 
clinically. The patients to the right of zero are patients that the model predicted could 
have received a higher MLD than was given clinically. For example, patients in the 20 Gy 
bin in Figure 29 are patients that could have theoretically received an increase of 20 Gy to 
their MLD. As expected, the most frequent occurrence is a small change between the 
model-generated MLD and the clinically achieved MLD. 
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A histogram of the difference in the model-generated prescriptions and the 
clinically achieved prescriptions is shown in Figure 30. The patients to the left of zero are 
the patients for who the model dictated that the prescription dose is reduced, while the 
patients to the right of zero are the patients for whom the model predicted that the doses 
could be escalated. Although there are 35 patients in the 0 Gy bin, the histogram shows 
that for most patients, there would be a change if the prescription was based on a model.  
 
 
 
Figure 29: A histogram of the difference between the model-generated MLD and the 
clinically achieved MLD. 
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Table 17: The overall clinically achieved prescription, model generated 
prescription, and changes in prescription for the entire patient population. 
 
 
 
 
 
 
 
 
 
The mean, median, and range of the change in prescription doses are shown in Table 17.  
 Clinical 
Rx (Gy) 
Model Rx 
(Gy) 
Model Rx – Clinical 
Rx (Gy) 
Absolute Rx 
Difference (Gy) 
Mean 65.4 62.7 -2.7 10.0 
Median 63.0 63.7 -1.7 6.0 
Range 60.0-72.0 40.0-100.0 -29.6 – 37.0 0-37.0 
 
The average difference between the model generated plans and the clinically used plans 
was a reduction of -2.7 Gy (with a median value of -1.7 Gy). The range of changes in 
prescription include a dose reduction of 29.6 Gy and a dose escalation of 30 Gy. In order 
Figure 30: A histogram of the differences between the model-generated prescriptions 
and the clinically achieved prescriptions. 
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to quantify the change in prescription for each patient, regardless of the sign, we 
calculated the absolute value in the changes in prescription. The mean and the median 
absolute changes were 10 Gy and 6 Gy respectively, suggesting that for most patients, 
using the model to generate a prescription dose will result in a change of at least 6 Gy in 
either direction (dose escalation or de-escalation). The mean and median changes in 
prescription are both negative (-2.7 and -1.7 respectively from Table 17), implying that 
overall the model-predicted doses were lower than the clinically achieved doses. This 
occurred because for 31 patients, the dose-volume parameters for the clinically used plan 
exceeded the limits that were set for this study (prior to applying the model-determine 
MLD limit). Excluding these patients, the histogram reveals (Figure 31) that fewer 
patients appear to the left of zero, or fewer patients for whom the dose needs to be 
reduced.  
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Furthermore, Table 18 shows that the mean and median changes in prescription were -0.7 
Gy and 1.4 Gy, respectively, for the reduced patient cohort.  
 
 
 
 
 
 
 
Figure 31: A histogram of the difference between the model-generated prescription dose 
and the clinically achieved prescription dose for the reduced patient population. Patients 
were excluded if their clinical dose-volume metrics for the spinal cord, esophagus, or 
heart exceeded the set limits prior to dose escalating or de-escalating. 
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Table 18: The overall clinically achieved prescription, model generated 
prescription, and changes in prescription for the reduced patient population. 
Patients were excluded if their clinically achieved dose-volume parameters for the 
spinal cord, esophagus, or heart exceeded the limits set for the study (prior to 
applying the model-determined MLD limit). 
 
 
 
 
 
 
 
 
 
 Clinical Rx 
(Gy) 
Model Rx 
(Gy) 
Model Rx – 
Clinical Rx (Gy) 
Absolute Rx 
Difference (Gy) 
Mean 65.4 65.1 -0.7 10.1 
Median 63.0 64.5  1.4 5.8 
Range 60.0-72.0 40.0-100.0  -29.6 – 37.0 0-37.0 
 
 
These values are closer to zero than the values shown in Table 17. It is also important to 
point out that when the absolute value of the changes is taken for the reduced patient 
cohort, the median change for the entire patient population is 5.8 Gy, indicating that for 
most individual patients using the model will result in a change (dose escalation or de-
escalation) of at least 5 Gy. 
The histogram of the change in prescription according to the presence of 
pneumonitis is shown in Figure 32. 
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The patients that developed severe radiation pneumonitis are shown as a separate group in 
Figure 32. As expected, most of the patients that developed radiation pneumonitis appear 
to the left of zero, indicating that for those patients the model predicted that the 
prescription doses needed to be reduced.  
 The personalized model-determined lung limits (and subsequently prescription 
values) are highly dependent on the chosen complication probability. We investigated the 
effect of choosing different complication probabilities on the prescription results. In 
addition to the nominal complication probability value of 22.6%, we chose to investigate 
complication probabilities of 20% and 25%. The histogram shown in Figure 33 displays 
Figure 32: A histogram of the difference in prescriptions according to the presence or 
absence of severe pneumonitis. 
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the change in prescription for the 20% complication probability simulation and the 25% 
complication probability simulation. As expected, the simulation using the 25% 
complication probability had fewer patients with a negative change in prescription and 
more patients with a positive change in prescription than the simulation using the 20% 
complication probability. These results are quantified in Table 19. The mean and median 
changes in prescription are higher for the 25% complication probability simulation than 
for the 20% complication probability simulation. These data suggest that overall, as the 
complication probability is increased the change in prescription will be skewed towards 
an increase in dose prescription for each patient. 
 
Figure 33: A histogram of the difference between the model-generated prescription and 
the clinically achieved prescription displayed according to different complication 
probabilities. 
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Table 19: Mean and median change in prescription for the 20% complication 
probability simulation and the 25% complication probability simulation. 
 
 
 
 
 
 
 
 
 
 
Table 20: Data showing the dose limiting organ for the simulation using the 22.6% 
complication probability.  
 
 
 
 
 
 
 
 
 
 
 Clinical 
Rx (Gy) 
NTCP = 20% 
Model Rx – 
Clinical Rx (Gy) 
NTCP = 25% 
Model Rx – Clinical 
Rx (Gy) 
Mean 65.4 -0.3 2.5 
Median 63.0 -2.9 0.1 
 
The dose limiting organs for the simulation using the 22.6% complication 
probability are shown in Table 20. As expected, the model-derived lung dose limit was 
the most frequent dose limiting organ. The lung limit was the limiting factor for 54% of 
patients, the cord max dose was the limit for 40% of patients, the esophagus was the limit 
for 4% of patients, and the heart was the limiting organ for 2% of patients.  
Dose-volume limit 
Number of 
patients (%) 
Model generated lung 
limit 77 (54%) 
Cord 55 (40%) 
Esophagus 6 (4%) 
Heart 3 (2%) 
Table 21 shows the dose limiting organ for the simulations using the 20% complication 
probability and the 25% complication probability.  The model generated lung limit was 
the limiting factor for 59% of patients for the simulation where the complication 
probability was set at 20% and 50% for the simulation where the complication probability 
was set at 25%. As the complication probability is allowed to increase and the lung 
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Table 21: Data showing the dose limiting organ for the simulation using the 20% 
complication probability and the 25% complication probability. 
 
 
 
 
 
 
 
 
 
planning limit is relaxed, the model generated lung parameter becomes a less frequent 
limiting factor. 
Dose-volume limit 
NTCP = 20 
Number of 
patients (%) 
NTCP = 25 
Number of 
patients (%) 
Model generated lung 
limit 83 (59%) 70 (50%) 
Cord 50 (35%) 60 (42%) 
Esophagus 5 (4%) 8 (6%) 
Heart 3 (2%) 3 (2%) 
 
Discussion 
 The most significant finding of the virtual simulation is that for individual 
patients, using a model-generated personalized MLD limit would result in a different 
prescription than what was used clinically.  The histogram of the difference in the MLD 
underlines that for individual patients the model based on SNPs predicts a different MLD 
to the patient than was clinically delivered. When the personalized MLD limit is used to 
determine a model-based prescription, the histogram demonstrates that for individual 
patients a change will result in the prescription dose. Furthermore, regardless of the 
complication probability used, the median change in the model-determined prescription 
and the clinically achieved prescription is over a clinically significant value of 5 Gy 
(Table 17, 18, 19). If the SNP findings are verified in independent patient cohorts, the 
prescription changes illustrated in this study would reduce toxicity in certain patients and 
help push the prescription dose to the maximum tolerable value. 
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 The direction of the change in prescription (dose escalation versus dose de-
escalation) is dependent on several factors. First, the direction of the change in 
prescription is dependent on the sample population used for the modeling study. Using a 
complication probability of 22.6% the overall change in dose prescription was negative 
(indicating a dose reduction) for our patient cohort (Table 17). However, when a reduced 
patient cohort was used that excluded patients for whom initial clinical values exceeded 
our dose limits, the changes in prescription were around 0, indicating that the positive and 
negative changes cancelled out (Table 18).  The overall change in prescription is also 
dependent on the exact complication probability that is used. As the complication 
probability is increased, the lung dose limit is relaxed, and we are able to increase the 
prescription dose (Figure 33).  These results suggest that if using the data in the current 
study to design a clinical trial, the complication probability and study cohort will have to 
be taken into account. The allowable complication probability is a clinical decision and 
must consider the tumor control as well as the normal tissue toxicity. As with any new 
technology or trial, a logical starting point to use (for the complication probability) is the 
current existing paradigm in the clinic.  Furthermore, each patient population will contain 
patients whose clinical dose-volume parameters exceed the allowable limits because the 
physician made a clinical decision to sacrifice normal tissue toxicity for tumor control. 
We demonstrated the effect of these patients on the overall prescription dose change by 
running a simulation where they were excluded from our analysis. In a clinical trial, one 
way to account for these patients is to artificially increase the allowable complication 
probability.  
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 The most frequent dose limiting organ observed was the lung, followed by the 
spinal cord, esophagus, and the heart (Table 20). These results are in line with what has 
been observed in the clinic. For thoracic treatment planning, the most frequent dose 
limiting organ is often the lung, followed by either the spinal cord or the esophagus 
depending on the location of the tumor. Our results demonstrated that as the allowable 
lung complication probability is increased the lung limit is relaxed and therefore is a 
limiting organ for fewer cases. 
 Van Baardwijk et al (49) performed a simulation study using 65 NSCLC patients 
where a lung dose limit and a spinal cord limit were used to escalate the doses. Although, 
the Van Baardwijk et al (49) study did not use genetic biomarkers (SNPs) in their dose 
prescription scheme, it is pertinent to compare the results of the 2 studies. The Van 
Baardwijk et al (49) used a nominal starting prescription of 60 Gy, a MLD limit of 19 Gy, 
and a spinal cord limit of 54 Gy for each patient. They found that on average they could 
increase the tumor dose by 6.6 Gy using a MLD limit of 19 Gy and a spinal cord limit of 
54 Gy. The 6.6 Gy change in target dose is in line with our reported change of around 6 
Gy (Table 17). However, it should be noted that we report a median change of 6 Gy 
(either escalation or de-escalation) in target dose for the entire patient population, while 
Van Baardwijk et al (49) report an average escalation in target dose of 6.6 Gy. The 
differences can be attributed to several factors. The population studies used in our 
simulation and the simulation provided  by Van Baardwijk et al (49) are different. The 
patients in our cohort received prescription doses ranging from 60 to 72 Gy, while all of 
the patients in the Van Baardwijk et al (49) study started with nominal prescription doses 
of 60 Gy. Furthermore, Van Baardwijk et al (49) used a population-based MLD limit of 
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19 Gy while we used individualized MLD limits that are determined from a model that 
incorporates biomarkers. Furthermore, our patient cohort contained patients for whom the 
dose-volume metrics for the spinal cord, esophagus, and heart exceeded our set limit prior 
to any escalation or de-escalation. Despite the differences in study design, both studies 
illustrate in silico, that a change in dose to the target for lung cancer patients can be 
achieved by prescribing doses that fully utilize the maximum allowable dose values to the 
normal tissue organs. Our results and those presented by Van Baardwijk et al (49) 
demonstrate the importance of performing simulation studies. Prior to conducting dose 
personalization clinical trials, simulation studies are needed to demonstrate the potential 
gain for the patient. 
 The current study uses a lung NTCP model to derive a personalized MLD limit 
that is in turn used to determine a personalized dose prescription for each patient. As 
modeling methods improve and more data is collected, it is possible that more patient and 
clinical factors will be found to be associated with the risk of developing radiation 
pneumonitis. In future work, these additional factors can be incorporated into the model 
to further personalize the MLD limit and the prescription dose. Furthermore, the concept 
of using a predictive model to determine a personalized dose limit can be extended to the 
esophagus, spinal cord, and liver, as data for those organs are accumulated. In this study, 
a predictive model was used exclusively to scale the prescription dose, in future work it 
will be possible to use an NTCP model to help with treatment planning. For example, if it 
is determined by the toxicity model that a patient can withstand a higher MLD, then dose 
can be taken off another organ (the spinal cord for example) and pushed through the lung. 
Furthermore, the model can be used to help decide which treatment modality to use for a 
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patient. If the model-determined MLD limit cannot be achieved with 3D-CRT then the 
toxicity model can provide further justification to use either IMRT or proton radiation 
therapy. While the hypothesis that proton treatment plans provide more favorable DVHs 
than photon treatment plans is still under investigation, for individual patients using a 
different treatment modality may enable the model determined limit to be achieved. The 
re-planning step was performed for 2 patients to illustrate the principle. The 2 patients 
were treated with 3D-CRT and had MLDs of 19.48 and 28.48 Gy. The model-determined 
limit was 17.81 Gy for the patient that received 19.48 Gy, and 26.16 Gy for the patient 
that received 28.48 Gy. Under the original assumptions of the simulation the prescription 
for these 2 patients would be lowered. However, experienced dosimetrists re-planned the 
patients with IMRT and protons. The 3D-CRT, IMRT, and proton treatment plans for one 
of patients are shown in Figure 34. Both the IMRT and protons plans results in MLDs 
below the model-determined limit for both patients (Table 22). The provided example 
illustrates that for certain patients, the personalized MLD limit may be achieved by re-
planning instead of lowering the prescription dose. The model-determined MLD limit can 
be used in this manner to justify the use of more advanced modalities such as IMRT and 
proton therapy.  
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Table 22: Re-planning example for 2 patients. The 3D-CRT, IMRT and Proton 
MLDs are shown. The model determined MLD limit is also displayed. 
 
 
 
 
 
 
 
 
 
 
 
 3D – CRT 
MLD 
IMRT 
MLD 
Proton 
MLD 
MLD Limit 
Patient 1 19.48 12.77 8.45 17.81 
Patient 2 28.48 24.12 21.74 26.16 
 
The work presented in this study is a proof of principle simulation and more work 
is needed before the proper use of a toxicity model can be determined. The most 
important work remaining is to verify the SNP results. Because of the large number of 
3D-CRT IMRT 
Protons 
Figure 34: Example of a 
patient that was re-
planned such that the 
model-determined MLD 
limit could be achieved. 
Planes of dose 
distributions are shown 
for 3D-CRT, IMRT, and 
protons for one patient. 
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SNPs available for investigation, there is a high probability of finding a significant 
association between SNPs and pneumonitis. In other words, when a large number of 
SNPs are investigated, there is a high probability of finding false positives. Therefore, 
work is underway to validate the SNPs in an independent patient cohort. It should be 
noted that the SNPs used for the current study were not randomly selected but were 
chosen because of their association with the inflammation process (38). Finally, it should 
be noted that this study does not suggest that the proper use of this model is to replace the 
current clinical paradigm. The model alone cannot be used to make clinical decision 
about the dose to the tumor. The model does not replace common sense, the clinical 
judgment of the physician, insurance considerations, or practical considerations. 
However, we believe that the model can be used as a tool and guide to help physicians 
make clinical decision. In our clinic, thoracic physicians implicitly (in some cases 
explicitly) take into account factors such as concurrent chemotherapy, prior surgery, and 
PFT data when deciding how much lung dose is safe to deliver. With increased data and 
improved modeling methods more factors may be found to be predictive for toxicity, and 
a model used in a manner described by the current study can aide physicians in making 
clinical decisions about how much dose to deliver to the lung. 
Conclusion 
 The current study presents a virtual proof of principle simulation trial where a 
personalized model-determined lung dose limit was used to change the prescription dose. 
It was determined that for individual patients the model generated prescription was 
different than the clinically achieved prescription. The working hypothesis for this study 
is accepted; the median change for an individual patient was 5.8 Gy. The magnitude and 
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direction of the change was dependent on the selected complication probability. 
Furthermore, we found that the model determined lung limit was the most frequent dose 
limiting organ. As more factors are found to be associated with normal tissue toxicity, a 
model used in the manner described by the current study can help physicians in 
determining how much dose can safely be delivered to the tumor and normal tissues. 
Conclusions 
Study uncertainties 
 Uncertainties associated with each individual specific aim have been noted in 
previous sections. For example, the uncertainty associated with calculating ventilation 
images was investigated in specific aim 1, the uncertainty of using SNPs was noted in 
specific aim 3, and the uncertainty of using the GTV centroid analysis was discussed in 
specific aim 1. In addition to uncertainties associated with each specific aim there are 
several modeling uncertainties that affect all dose-response modeling work. The biggest 
overall limitation in the dose response modeling field is the toxicity scoring system. The 
scoring system used for performing a toxicity modeling analysis is subjective. It is 
subjective to the patient as well as the clinician. For example, one of the criteria for 
scoring radiation pneumonitis is patient-reported symptoms. This is subjective because 
certain patients may complain more than others or certain patients may have poor lung 
conditions prior to beginning treatment and therefore don’t report changes in symptoms. 
Another portion of the radiation pneumonitis scoring criteria is medical intervention. The 
medical intervention criterion is subjective because some physicians may feel that 
medical intervention is warranted in certain situations while other physicians may think 
that no action is necessary. The subjectivity of the scoring system due to both the 
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clinician and the patient adds uncertainty into the dose-response modeling process 
because severe (grade 3-5) radiation pneumonitis was the end point for all of our analysis. 
Another limitation to dose-response modeling is the sparse data that is available. The 
number of patients developing severe toxicity is low, which is a positive outcome for the 
patient. However, the low number of events (patients developing radiation pneumonitis) 
hinders the statistical power of our modeling methods. Finally, in some cases the toxicity 
reported may not be due to radiation therapy. Patients with NSCLC are often also 
afflicted with other diseases such as COPD, emphysema, and heart disease. A number of 
symptoms that may be perceived as being caused by radiation therapy can also be caused 
by the patient’s prior existing conditions. In extreme conditions, even grade 5 toxicity 
(death) may be difficult to identify because the patient’s death may be a result of non-
radiation causes (such as tumor progression or pre-existing lung conditions). 
 The other important factor that adds uncertainty into thoracic dose-response 
modeling is organ motion. Specifically, intra-fractional organ motion due to breathing 
and inter-fractional organ motion due to set-up uncertainty can cause a deviation between 
the intended and delivered dose distributions. Therefore, it is possible that the dose 
distributions that were used for the dose-response analysis may not be a completely 
accurate representation of the delivered doses. However, studies suggest that motion 
causes the largest uncertainty in the dose calculations in heterogeneous dose regions (85) 
and that motion minimally affects the accuracy of dose calculations to normal tissue when 
evaluated using the DVH (86). Organ motion also causes uncertainty in the organ 
contouring process. With the routine clinical use of 4DCT, multiple imaging datasets are 
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available for contouring of the normal tissue organs. The image set chosen to contour the 
organs of interest may affect the contour itself.  
Conclusions 
 In specific aim 1 we used our large NSCLC patient database to investigate the 
relationship between the spatial location of the deposited lung dose and severe radiation 
pneumonitis. We performed the analysis using the GTV centroid as well as the entire 3D 
dose distribution. It was determined that for our patient cohort the spatial location of the 
dose does not influence the risk of radiation pneumonitis.  
 In specific aim 2 we investigated the utility of 4DCT-based ventilation imaging in 
assessing lung injury. We first presented a unique dataset of mid-treatment weekly 
calculated ventilation images. We did not find a consistent pattern of ventilation change 
as a function of dose. However, we did find that ventilation and ventilation change was a 
function of anatomy. Specifically, our results showed that pre-treatment ventilation 
values were lower in lobes that contained the tumor, and if the tumor decreased in size, 
the lobe was likely to re-inflate and ventilation would increase. Conversely, our results 
showed that when there was no change in either the tumor or normal tissue anatomy, 
there was no change in the ventilation distribution. The second portion of specific aim 2 
incorporated pre-treatment ventilation images into a dose response model. Although there 
were some promising results relating pre-treatment function (as measured by ventilation) 
and severe radiation pneumonitis we were not able to significantly improve the fit of our 
model using ventilation imaging. We believe more patients may be able to clarify the 
relationship between dose to highly ventilated portions of the lung and radiation 
pneumonitis. 
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 In specific aim 3 we performed a proof of principle virtual simulation study where 
a personalized model-determined lung limit was used to scale the prescription dose. We 
found that for individual patients, using the personalized model lung dose limit resulted in 
a different prescription than what was achieved clinically for the patient. The median 
difference between the model-generated prescription and the clinically achieved 
prescription was 5.8 Gy. Our simulation results demonstrated the methodology and 
preliminary data that could eventually be used to design a clinical trial. More work is 
needed to verify the biomarkers used in our study, add additional factors into the 
predictive model, and determine the proper use of the toxicity model within the treatment 
design paradigm. 
Clinical significance of research 
 The spatial study presented in this work adds a significant clinical contribution to 
existing literature and clinical knowledge. Because of the size of our patient cohort and 
the rigor of our modeling methods, we believe the current study provides an important 
addition to the existing knowledge about the relationship between spatial location and 
radiation pneumonitis. The spatial location within the lung is a pertinent clinical topic 
because physicians need to know whether it is important to take the spatial location of the 
tumor within the lung into account when considering how much dose can safely be 
delivered to the healthy lung. Furthermore, the spatial methods presented in the current 
work can be extended to other organs and other treatment modalities. For example, it may 
be of interest whether or not toxicity is dependent on the spatial location of the dose 
within the esophagus or liver.  The methods used in this study can also be extended to 
thoracic proton therapy. 
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 Although we did not find a statistically significant relationship between 
ventilation-based functional information and radiation pneumonitis, specific aim 2 
provided some promising clinical results. To our knowledge, the serial ventilation study 
was the first study that has investigated the mid-treatment changes in ventilation. Mid-
treatment changes in ventilation may be useful for the clinician to assess. In theory, the 
physician may take changes in lung function into account when deciding on whether or 
not to adapt the radiation treatment plan. By incorporating pre-treatment ventilation data 
into modeling we have provided an important step in using imaging to assess lung 
function and predict toxicity. There has been a lot of recent interest in using imaging to 
assess and predict for toxicity (40-43, 59-62).  However, the results have been limited by 
the number of patients enrolled in the studies and by the incomplete understanding and 
assessment of lung function. In future work, lung function will be assessed by a 
combination of imaging modalities (ventilation, perfusion, diffusion, and inflammation). 
The ventilation results presented in this work may provide one of the important pieces 
necessary to gain a complete understanding of lung function. This work was not only 
important from a modeling aspect but from a 4DCT-based ventilation aspect as well. 
There has been a lot of recent interest in 4DCT-based ventilation calculation 
methodology and using 4DCT-based ventilation imaging to reduce dose to highly 
ventilated portions of the lung. However, there has been no data to suggest using 
ventilation imaging in treatment planning will reduce clinical toxicity. This is the first 
study attempting to relate dose to ventilated portions of the lung and clinical symptoms. 
Although we did not find a significant result, we show some promising data that can 
provide the basis for future work relating dose, ventilation, and clinical symptoms. 
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 In the virtual simulation trial, we have provided the methodology that can be used 
to determine personalized lung dose limits and subsequently personalized prescription 
doses. As mentioned in specific aim 3, this is something that thoracic physicians may 
implicitly do already. When deciding how much dose can safely be delivered to the 
healthy lung, physicians may take into account factors such as surgery status, 
chemotherapy status, and PFT scores. As more factors are determined to be predictive of 
radiation pneumonitis, using a model in the manner shown in Specific Aim 3 can be a 
useful tool and guide for clinicians in determining a personalized lung dose limit and 
subsequently a personalized prescription. More work is necessary before such a model 
can be utilized in the clinic; however, the work done in Specific Aim 3 provides the 
framework in which a model can be used to derive a personalized prescription dose.  
Future Work 
 Future work relating to the specific studies is discussed within each specific aim. 
For example, as more patients are gathered for the spatial study (specific aim 1) it would 
be useful to perform the 3D spatial dose analysis for smaller cohorts of patients that are 
grouped according to disease stage. For the ventilation study (both the serial ventilation 
study and the pre-treatment ventilation study), more patients are needed. Furthermore, it 
would be informative to investigate 4DCT-based ventilation images acquired several 
weeks or months after the completion of therapy, since radiation damage (to the tumor 
and normal tissue) occurs after the completion of therapy. For the virtual simulation 
study, the next important step is to verify the SNP data. Another possible continuation of 
the virtual trial is to include more factors (such as patient smoking status) that may be 
predictive of radiation pneumonitis into the modeling simulation. 
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 There are a several different ways in which the current research can be extended. 
One important area is the toxicity scoring system. As mentioned in previous section, the 
toxicity scoring system for radiation pneumonitis is subjective to the patient as well as the 
clinician. More work is needed to generate an objective toxicity scoring system. One 
potential method involves the use of imaging as a surrogate for clinical symptoms. 
However, since clinical symptoms are the important end point to the clinician, work is 
needed relating imaging based scoring of radiation pneumonitis and symptom based 
scoring of radiation pneumonitis. 
 Imaging can also be used to help identify early changes in lung function that can 
predict for radiation pneumonitis. In the current study, we investigated ventilation based 
changes; however, work is needed to get a complete understanding of lung function. In 
future work, more information about lung function could be gained by combining 
imaging modalities that assess different aspects of lung function. 
 It is also possible to extend the current modeling work to other treatment 
modalities and other treatment sites. For example, the spatial analysis could be extended 
to patients undergoing proton therapy. The modeling work can be applied to other organs 
such as the brain, liver, and esophagus. Specifically, it would be informative to apply the 
spatial work to the liver and esophagus and incorporate functional imaging into 
predictions methods for the brain and liver. 
 There is also great potential to incorporate modeling work into hypo-fractionated 
treatments. Because of their convenience and promising survival rates stereotactic body 
radiotherapy (SBRT) has been increasing in popularity. However, relatively little is 
known about thoracic toxicity associated with SBRT (6). More work is needed to relate 
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basic dose-volume metrics and SBRT toxicity. Once a dose-volume relationship has been 
established, further work incorporating spatial and functional information can be 
performed.  Another possibility is to apply this work to re-treatments. As survival rates 
increase radiation re-treatments are becoming more common and as is the case with 
SBRT, there is relatively little toxicity data for patients undergoing re-treatments. As data 
is collected, the first step will be to establish a dose-volume relationship and then test for 
other factors that may be predictive of toxicity. 
Response to hypothesis 
 The purpose of this work was to incorporate spatial and functional information 
into a predictive model and determine whether the fit of the model to the data could be 
improved. In a strict sense, the hypothesis is rejected; we were not able to significantly 
improve the model fit to the data. Specifically, incorporating spatial information and 
ventilation-based functional information did not significantly improve the fit of the 
model. Although the hypothesis was rejected the study had some important findings. We 
did not find a correlation between the spatial location of the dose and radiation 
pneumonitis. We found that ventilation and ventilation change was a function of the 
changing thoracic anatomy. We presented some promising (although not statistically 
significant) results relating pre-treatment ventilation and radiation pneumonitis. Finally, 
we presented a simulation study where a personalized model-determined lung dose limit 
was used to change the prescription dose. It was determined that for individual patients 
the model generated prescription was different than the clinically achieved prescription. 
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